<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Dent. Med.</journal-id>
<journal-title>Frontiers in Dental Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Dent. Med.</abbrev-journal-title>
<issn pub-type="epub">2673-4915</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fdmed.2025.1612522</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Dental Medicine</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Salivary gland transcriptomic analysis and immunophenotyping in the IL-14&#x03B1; transgenic mouse model of Sj&#x00F6;gren&#x0027;s disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Woods</surname><given-names>Lucas T.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/855082/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib>
<contrib contrib-type="author"><name><surname>Jasmer</surname><given-names>Kimberly J.</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/901518/overview" /><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib>
<contrib contrib-type="author"><name><surname>Mu&#x00F1;oz Forti</surname><given-names>Kevin</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/2792278/overview" /><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib>
<contrib contrib-type="author"><name><surname>Kearns</surname><given-names>Alex</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/3115481/overview" /><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Weisman</surname><given-names>Gary A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref><uri xlink:href="https://loop.frontiersin.org/people/920599/overview" /><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib>
</contrib-group>
<aff id="aff1"><label><sup>1</sup></label><institution>Department of Biochemistry, University of Missouri</institution>, <addr-line>Columbia, MO</addr-line>, <country>United States</country></aff>
<aff id="aff2"><label><sup>2</sup></label><institution>Christopher S. Bond Life Sciences Center, University of Missouri</institution>, <addr-line>Columbia, MO</addr-line>, <country>United States</country></aff>
<aff id="aff3"><label><sup>3</sup></label><institution>Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry</institution>, <addr-line>Louisville, KY</addr-line>, <country>United States</country></aff>
<aff id="aff4"><label><sup>4</sup></label><institution>Section on Hematology and Oncology, Department of Medicine, The University of Chicago</institution>, <addr-line>Chicago, IL</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by"><p><bold>Edited by:</bold> Wen Zhou, Case Western Reserve University, United States</p></fn>
<fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Xiangsong Bai, Peking University, China</p>
<p>Hao Shih, China Medical University Hospital, Taiwan</p></fn>
<corresp id="cor1"><label>&#x002A;</label><bold>Correspondence:</bold> Gary A. Weisman <email>weismang@missouri.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub"><day>08</day><month>07</month><year>2025</year></pub-date>
<pub-date pub-type="collection"><year>2025</year></pub-date>
<volume>6</volume><elocation-id>1612522</elocation-id>
<history>
<date date-type="received"><day>15</day><month>04</month><year>2025</year></date>
<date date-type="accepted"><day>13</day><month>06</month><year>2025</year></date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2025 Woods, Jasmer, Mu&#x00F1;oz Forti, Kearns and Weisman.</copyright-statement>
<copyright-year>2025</copyright-year><copyright-holder>Woods, Jasmer, Mu&#x00F1;oz Forti, Kearns and Weisman</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Sj&#x00F6;gren&#x0027;s disease (SjD) is a systemic autoimmune disorder primarily affecting the exocrine glands and characterized by dry mouth and dry eye, the presence of anti-SSA and/or anti-SSB autoantibodies in blood serum, and chronic lymphocytic infiltration of salivary and lacrimal glands (<italic>i.e.</italic>, sialadenitis and dacryoadenitis, respectively). In addition to reduced quality of life, SjD patients experience severe oral health complications and are at increased risk of developing B cell lymphoma. Because current SjD treatments primarily focus on oral and ocular symptom management, identifying initiating factors and mechanisms of disease progression may offer new therapeutic insights for SjD. The interleukin-14&#x03B1; transgenic (IL-14&#x03B1;TG) mouse model of SjD recapitulates many aspects of human SjD, including progressive sialadenitis, loss of salivary gland function, and development of B cell lymphoma. We utilized immunofluorescence, flow cytometry, bulk RNA sequencing and spatial transcriptomic analyses to identify immune cell subpopulations and differentially expressed genes (DEGs) in submandibular glands of IL-14&#x03B1;TG Sj&#x00F6;gren&#x0027;s-like mice and age-matched C57BL/6 mouse controls. We further compared the gene ontology of DEGs in IL-14&#x03B1;TG mice to DEGs identified in minor salivary gland biopsies from SjD patients and healthy volunteers. Results demonstrated significantly increased sialadenitis in IL-14&#x03B1;TG compared to C57BL/6 mice that correlated with an increased proportion of marginal zone B cells infiltrating the submandibular gland. Whole transcriptome analyses showed substantial overlap in enriched DEG ontology between IL-14&#x03B1;TG mouse submandibular gland and SjD patient minor salivary gland, compared to C57BL/6 mice and healthy human volunteer controls, respectively. Lastly, we spatially resolved DEG expression and localization within IL-14&#x03B1;TG salivary glands, marking the first publication of a spatial transcriptomic dataset from submandibular glands in a SjD mouse model.</p>
</abstract>
<kwd-group>
<kwd>Sj&#x00F6;gren&#x0027;s disease</kwd>
<kwd>salivary gland</kwd>
<kwd>spatial transcriptome</kwd>
<kwd>interleukin-14&#x03B1; transgenic</kwd>
<kwd>RNAseq</kwd>
<kwd>sialadenitis</kwd>
</kwd-group><contract-num rid="cn001">R01DE029833, R01DE029833-S1</contract-num><contract-sponsor id="cn001">National Institute of Dental &#x0026; Craniofacial Research of the National Institutes of Health</contract-sponsor><contract-sponsor id="cn002">Wayne L. Ryan fellowship from The Ryan Foundation</contract-sponsor><counts>
<fig-count count="9"/>
<table-count count="2"/><equation-count count="0"/><ref-count count="90"/><page-count count="19"/><word-count count="0"/></counts><custom-meta-wrap><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Oral-Systemic Immunology</meta-value></custom-meta></custom-meta-wrap>
</article-meta>
</front>
<body><sec id="s1" sec-type="intro"><title>Introduction</title>
<p>Sjogren&#x0027;s disease (SjD) is a systemic autoimmune disease characterized by dry eye (<italic>i.e.</italic>, keratoconjunctivitis sicca) and dry mouth (<italic>i.e.</italic>, xerostomia) resulting from chronic lacrimal and salivary gland dysfunction, respectively (<xref ref-type="bibr" rid="B1">1</xref>). In addition to increased oral health complications, such as dental caries, candidiasis and periodontitis that degrade quality of life, SjD patients often experience systemic manifestations including pulmonary dysfunction, musculoskeletal pain, fatigue and sleep disturbances (<xref ref-type="bibr" rid="B2">2</xref>). Prominent among systemic manifestations is the increased risk of B cell lymphoma in SjD patients, particularly non-Hodgkin mucosa-associated lymphoid tissue (MALT) lymphoma that most often develops in salivary glands, lymph nodes and lung tissues where disease symptoms are active (<xref ref-type="bibr" rid="B3">3</xref>). Clinical diagnosis of SjD most commonly occurs in women 40&#x2013;55 years of age, with an estimated female-to-male ratio of 9:1, and classification criteria have changed over time due to the complexity and systemic nature of SjD (<xref ref-type="bibr" rid="B4">4</xref>). In 2016, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) jointly designed and clinically validated consensus SjD classification methodology for patients with oral or ocular dryness that uses a combination of weighted factors, including the presence of anti-SSA/Ro autoantibodies in blood serum, a positive biopsy showing lymphocytic infiltration of the minor salivary glands (<italic>i.e.</italic>, sialadenitis), and quantitative measurements of ocular staining, saliva flow rate and tear production (<xref ref-type="bibr" rid="B1">1</xref>).</p>
<p>Due to the lack of curative therapeutics, current SjD treatments focus on oral and ocular symptom management to improve patient quality of life and systemic anti-inflammatory treatments to limit extra-glandular disease manifestations. Treatments for oral dryness include non-pharmacological interventions such as lozenges, chewing gum, and saliva substitutes and pharmacological interventions such as administration of the muscarinic receptor agonists pilocarpine and cevimeline to stimulate saliva production (<xref ref-type="bibr" rid="B5">5</xref>). Treatments for systemic manifestations of SjD include anti-inflammatory and anti-rheumatic drugs such as glucocorticoids, hydroxychloroquine and methotrexate for musculoskeletal pain and respiratory symptoms. However, data regarding clinical efficacy of these treatments is limited (<xref ref-type="bibr" rid="B6">6</xref>). Because SjD patients exhibit many hallmarks of B cell hyperactivity, including the development of anti-SSA/Ro autoantibodies, the presence of ectopic germinal centers in the salivary glands, and increased risk of B cell lymphoma (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>), B cell-targeted therapies have also been utilized to treat systemic symptoms of SjD. In clinical trials, the anti-CD20 monoclonal antibody rituximab is the most heavily studied B cell-targeted therapy (<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>) along with the anti-CD22 monoclonal antibody epratuzumab (<xref ref-type="bibr" rid="B12">12</xref>), the anti-B lymphocyte stimulator (BlyS; BAFF) monoclonal antibody belimumab (<xref ref-type="bibr" rid="B13">13</xref>) and the small molecule inhibitor remibrutinib that targets Bruton&#x0027;s tyrosine kinase (<xref ref-type="bibr" rid="B14">14</xref>). However, due to the lack of consensus data on the efficacy of B cell-targeted therapies in SjD, EULAR recommendations limit their use to patients with severe refractory SjD after failure of conventional therapies (<xref ref-type="bibr" rid="B5">5</xref>). Considering the limited treatment options for symptom management and the lack of effective treatments for underlying disease processes, identification of disease-initiating factors and mechanisms of progression may offer new therapeutic insights for SjD treatment.</p>
<p>Investigating SjD progression in human patients presents difficulties resulting from unknown disease etiology and the potential delay between disease onset and clinical diagnosis. Therefore, numerous SjD animal models have been developed to study disease progression, including spontaneous models such as non-obese diabetic (NOD) mouse derivatives, knockout models including <italic>CD25</italic><sup>&#x2212;/&#x2212;</sup> and <italic>Id3</italic><sup>&#x2212;/&#x2212;</sup> mice, transgenic models such as the BlyS/BAFF transgenic mouse, and induced models following mouse immunization with muscarinic receptor 3 or SSA/Ro antigens (<xref ref-type="bibr" rid="B15">15</xref>). The interleukin-14&#x03B1; transgenic (IL-14&#x03B1;TG) mouse model of SjD was generated by over-expressing human interleukin-14 (alpha-taxilin; high molecular weight B cell growth factor) under the direction of the lymphoid <italic>IgH</italic> promoter in the C57BL/6 mouse background (<xref ref-type="bibr" rid="B16">16</xref>). IL-14&#x03B1;TG mice exhibit many aspects of B cell hyperactivation, including hypergammaglobulinemia, increased immunoglobulin production in response to T cell-dependent and -independent antigens, and increased levels of B cell subpopulations in the spleen and peritoneum (<xref ref-type="bibr" rid="B16">16</xref>). These mice also recapitulate many aspects of human SjD, including progressive sialadenitis, loss of salivary gland function and development of B cell lymphoma (<xref ref-type="bibr" rid="B16">16</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>).</p>
<p>The widespread application of whole transcriptome analysis through bulk and single-cell RNA sequencing (RNAseq) has greatly advanced our understanding of molecular pathways involved in SjD pathogenesis, highlighting previously unknown gene expression changes and cellular heterogeneity in SjD salivary gland biopsies (<xref ref-type="bibr" rid="B20">20</xref>&#x2013;<xref ref-type="bibr" rid="B24">24</xref>). Similarly, transcriptomic analyses of mouse salivary glands during development have elucidated the heterogeneity of salivary gland parenchyma from embryonic stage through adulthood (<xref ref-type="bibr" rid="B25">25</xref>). Other studies in SjD mouse models have identified previously unknown salivary and lacrimal gland signaling paradigms that are altered during SjD progression, including the downregulation of metabolic pathways involved in amino acid metabolism and fatty acid biosynthesis, the enrichment of diverse innate and humoral inflammatory pathways and the contributions of salivary epithelial cells to chronic immune dysregulation (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Unlike bulk and single-cell RNAseq, spatial transcriptomic analysis allows gene transcripts to be identified with their spatial context still intact and provides additional indications of cellular interactions within the tissue (<xref ref-type="bibr" rid="B28">28</xref>). By overlaying histological tissue sections on an array of barcoded oligo(dT) primers or pre-designed capture probes followed by RNAseq, mRNA transcripts can be quantified and localized without the limitation of dissociating individual intact cells from whole tissue that can stress or damage labile cells such as neurons (<xref ref-type="bibr" rid="B29">29</xref>). Spatial transcriptomics analysis has been previously utilized to probe epithelial-immune cell interactions and stratify acinar, ductal and T cell subsets within tissue niches of SjD minor salivary glands (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>) and, alongside bulk RNAseq, to identify tissue localization of differentially expressed genes (DEGs) and cell cluster-specific gene pathway enrichment in inflamed lacrimal glands of the NOD.B10-H2<sup>b</sup> mouse model of SjD (<xref ref-type="bibr" rid="B26">26</xref>).</p>
<p>Here, we utilized immunofluorescence, flow cytometry and bulk RNAseq analyses to compare immune cell subpopulations and differentially expressed genes in IL-14&#x03B1;TG and age-matched control C57BL/6 mouse submandibular glands (SMGs). We further compared the gene ontology of DEGs in IL-14&#x03B1;TG mice to DEGs identified in minor salivary gland biopsies from SjD patients and healthy volunteers. Lastly, we utilized spatial transcriptomic analyses to localize the expression of DEGs within the SMG and sublingual glands of IL-14&#x03B1;TG and C57BL/6 mice. To our knowledge, this is the first presentation of spatial transcriptomic data from submandibular and sublingual glands of an SjD mouse model.</p>
</sec>
<sec id="s2" sec-type="methods"><title>Materials and methods</title>
<sec id="s2a"><title>Mice</title>
<p>C57BL/6 (stock &#x0023; 000664) mice were purchased from Jackson Laboratories (Bar Harbor, ME) and IL-14&#x03B1;TG mice were housed at the Christopher S. Bond Life Sciences Center Animal Facility of the University of Missouri (Columbia, MO). Animals were housed in vented cages with 12&#x2005;h light/dark cycles and received food and water <italic>ad libitum</italic>. Age-matched female mice were used in all experiments and genotyping was performed by PCR, as previously described (<xref ref-type="bibr" rid="B16">16</xref>). Euthanasia was performed by terminal anesthesia with isoflurane followed by cervical dislocation, with efforts taken to minimize suffering. All experimental animal procedures were conducted in accordance with National Institutes of Health guidelines that were approved by the University of Missouri Animal Care and Use Committee (Protocol Number 38921).</p>
</sec>
<sec id="s2b"><title>Bright field and immunofluorescence microscopy</title>
<p>For bright field microscopy, mouse SMGs and sublingual glands (SLGs) were excised, fixed in 4&#x0025; (v/v) paraformaldehyde for 24&#x2005;h and dehydrated by incubation in 70&#x0025; (v/v) ethanol for 24&#x2005;h at 4&#x00B0;C. Samples were sent to IDEXX BioAnalytics (Columbia, MO), where they were embedded in paraffin, sectioned and stained with hematoxylin and eosin. Stitched images of whole submandibular and sublingual glands were captured on a Leica DMI6000B inverted microscope using LAS X software.</p>
<p>For immunofluorescence analysis, SMGs and SLGs were excised, embedded in OCT compound, snap frozen in 2-methylbutane cooled with liquid nitrogen and cryosectioned on a Leica CM3050 cryostat at the University of Missouri Advanced Light Microscopy Core (UMALMC) Facility. Cryosections were adhered to slides and then fixed in 4&#x0025; (v/v) paraformaldehyde for 20&#x2005;min at room temperature or in acetone at &#x2212;20&#x00B0;C for 10&#x2005;min (for detection of GL7), washed in PBS and placed for 1&#x2005;h at room temperature in blocking buffer containing 5&#x0025; (v/v) goat serum in PBS with mouse BD Fc Block (1:250, BD Biosciences). Sections were then stained for 16&#x2005;h at 4&#x00B0;C in blocking buffer containing the following conjugated primary antibodies: AlexaFluor 594 rat anti-B220 (1:200, Biolegend clone RA3-6B2), AlexaFluor 488 hamster anti-CD3 (1:200, ThermoFisher clone 145-2C11), Brilliant Violet 421 rat anti-CD169/Siglec-1 (1:200, Biolegend clone 3D6.112), AlexaFluor 594 hamster anti-CD11c (1:200, Biolegend clone N418) or FITC rat anti-GL7 (1:250, BD Biosciences clone GL7). For unconjugated primary antibodies, sections were stained for 16&#x2005;h at 4&#x00B0;C in blocking buffer containing rat anti-CD45 (1:100, Biolegend clone 30-F11) and rabbit anti-Aquaporin 5 (1:100, MilliporeSigma &#x0023;178615) antibodies, washed in PBS, then stained with AlexaFluor 594 goat anti-rat IgG (1:1,000, ThermoFisher &#x0023;A-11007) and AlexaFluor 488 goat anti-rabbit IgG (1:1,000, ThermoFisher &#x0023;A-11008) secondary antibodies for 1&#x2005;h at room temperature. Slides were then washed in PBS and coverslips mounted using Fluoroshield with DAPI (MilliporeSigma). Stitched and high-magnification SMG and SLG images were captured on a Leica STELLARIS 5 confocal microscope using LAS X software.</p>
</sec>
<sec id="s2c"><title>Flow cytometry</title>
<p>SMGs were isolated, finely minced in digestion media [RPMI-1640 media containing 5&#x0025; (v/v) fetal bovine serum, 2&#x2005;mM EDTA, 2.5&#x2005;mM CaCl<sub>2</sub> and 1&#x2005;mg/ml collagenase D (MilliporeSigma)], and placed in a shaking incubator for 2&#x2005;h at 37&#x00B0;C and 270&#x2005;rpm. Dispersed SMGs and isolated spleens were then passed through a 40&#x2005;&#x00B5;m cell strainer, washed in PBS and spleen homogenates were resuspended in red blood cell lysis buffer (Miltenyi Biotec) for 10&#x2005;min in the dark. Following a wash in PBS, cells were pelleted by centrifugation at 500&#x00D7;g at 4&#x00B0;C, resuspended in PBS, counted and aliquoted for analysis.</p>
<p>For antibody staining, 10<sup>6</sup> cells were resuspended in 100&#x2005;&#x00B5;l of PBS containing Zombie NIR viability dye (1:2,000) and mouse BD Fc Block (1:100), incubated for 15&#x2005;min in the dark, and then washed in cytometry buffer [0.5&#x0025; (w/v) bovine serum albumin, 2&#x2005;mM EDTA in PBS]. Cells were then resuspended in cytometry buffer containing 1:100 dilutions of each antibody in either the B cell or T cell panel (<xref ref-type="table" rid="T1">Table&#x00A0;1</xref>) and incubated for 1&#x2005;h at 4&#x00B0;C in the dark. Following a 5&#x2005;min wash in cytometry buffer, cells were fixed and permeabilized using the eBioscience FoxP3/transcription factor staining buffer set (ThermoFisher) per the manufacturer&#x0027;s protocol. Cells were then resuspended in eBioscience permeabilization buffer containing 1:100 dilutions of antibodies targeting intracellular antigens (denoted with &#x0023; in <xref ref-type="table" rid="T1">Table&#x00A0;1</xref>) and incubated for 16&#x2005;h at 4&#x00B0;C in the dark. Cells were then washed twice and resuspended in cytometry buffer for analysis, with an aliquot of unstained sample reserved for autofluorescence control. Fluorescence minus one (FMO) control samples and single-stained compensation controls were similarly prepared using spleen cells for FMOs and UltraComp eBeads Plus compensation beads (ThermoFisher), respectively. Samples were analyzed on a Cytek Aurora spectral flow cytometer at the University of Missouri Cell and Immunobiology Core Facility and spectral unmixing was performed using Cytek SpectroFlo software. Representative gating strategies for each panel are shown in <xref ref-type="sec" rid="s11">Supplementary Figures S1</xref> and <xref ref-type="sec" rid="s11">S2</xref>.</p>
<table-wrap id="T1" position="float"><label>Table 1</label>
<caption><p>Flow cytometry antibodies used for identification of B and T cell subpopulations, where &#x0023; denotes an intracellular antigen.</p></caption>
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="center"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th valign="top" align="left">FACS panel</th>
<th valign="top" align="center">Antigen</th>
<th valign="top" align="center">Fluorophore</th>
<th valign="top" align="center">Clone</th>
<th valign="top" align="center">Catalog number</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" rowspan="2">B and T cells</td>
<td valign="top" align="left">Viability dye</td>
<td valign="top" align="left">Zombie NIR</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">Biolegend 423106</td>
</tr>
<tr>
<td valign="top" align="left">CD45</td>
<td valign="top" align="left">VioBlue</td>
<td valign="top" align="left">REA737</td>
<td valign="top" align="left">Miltenyi 130-110-664</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="10">T cells</td>
<td valign="top" align="left">CD3&#x03B5;</td>
<td valign="top" align="left">PerCP/Cyanine 5.5</td>
<td valign="top" align="left">145-2C11</td>
<td valign="top" align="left">Biolegend 100328</td>
</tr>
<tr>
<td valign="top" align="left">CD4</td>
<td valign="top" align="left">Brilliant Violet 750</td>
<td valign="top" align="left">GK1.5</td>
<td valign="top" align="left">Biolegend 100467</td>
</tr>
<tr>
<td valign="top" align="left">CD8a</td>
<td valign="top" align="left">PE/Dazzle 594</td>
<td valign="top" align="left">53-6.7</td>
<td valign="top" align="left">Biolegend 100762</td>
</tr>
<tr>
<td valign="top" align="left">CD69</td>
<td valign="top" align="left">PE/Cyanine 7</td>
<td valign="top" align="left">H1.2F3</td>
<td valign="top" align="left">Biolegend 104512</td>
</tr>
<tr>
<td valign="top" align="left">CD279</td>
<td valign="top" align="left">PE</td>
<td valign="top" align="left">HA2-7B1</td>
<td valign="top" align="left">Miltenyi 130-102-299</td>
</tr>
<tr>
<td valign="top" align="left">FoxP3&#x0023;</td>
<td valign="top" align="left">APC</td>
<td valign="top" align="left">FJK-16s</td>
<td valign="top" align="left">Invitrogen 17-5773-82</td>
</tr>
<tr>
<td valign="top" align="left">CD25</td>
<td valign="top" align="left">APC/Cyanine 7</td>
<td valign="top" align="left">3C7</td>
<td valign="top" align="left">Biolegend 101918</td>
</tr>
<tr>
<td valign="top" align="left">GATA3&#x0023;</td>
<td valign="top" align="left">AlexaFluor 488</td>
<td valign="top" align="left">16E10A23</td>
<td valign="top" align="left">Biolegend 653808</td>
</tr>
<tr>
<td valign="top" align="left">ROR&#x03B3;t&#x0023;</td>
<td valign="top" align="left">PerCP/eFluor 710</td>
<td valign="top" align="left">B2D</td>
<td valign="top" align="left">Invitrogen 46-9681-82</td>
</tr>
<tr>
<td valign="top" align="left">CD183</td>
<td valign="top" align="left">Super Bright 600</td>
<td valign="top" align="left">CXCR3-173</td>
<td valign="top" align="left">Invitrogen 63-1831-82</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="10">B cells</td>
<td valign="top" align="left">CD19</td>
<td valign="top" align="left">PerCP</td>
<td valign="top" align="left">6D5</td>
<td valign="top" align="left">Biolegend 115532</td>
</tr>
<tr>
<td valign="top" align="left">B220 (CD45R)</td>
<td valign="top" align="left">APC</td>
<td valign="top" align="left">REA755</td>
<td valign="top" align="left">Miltenyi 130-110-710</td>
</tr>
<tr>
<td valign="top" align="left">CD5</td>
<td valign="top" align="left">PerCP/Cyanine5.5</td>
<td valign="top" align="left">53-7.3</td>
<td valign="top" align="left">Biolegend 100624</td>
</tr>
<tr>
<td valign="top" align="left">CD23</td>
<td valign="top" align="left">PE/CF594</td>
<td valign="top" align="left">B3B4</td>
<td valign="top" align="left">BD Biosciences 563986</td>
</tr>
<tr>
<td valign="top" align="left">CD21/CD35</td>
<td valign="top" align="left">PE</td>
<td valign="top" align="left">7E9</td>
<td valign="top" align="left">Biolegend 123410</td>
</tr>
<tr>
<td valign="top" align="left">GL7</td>
<td valign="top" align="left">AlexaFluor 488</td>
<td valign="top" align="left">GL-7</td>
<td valign="top" align="left">Invitrogen 53-5902-82</td>
</tr>
<tr>
<td valign="top" align="left">Bcl-6&#x0023;</td>
<td valign="top" align="left">BV421</td>
<td valign="top" align="left">K112-91</td>
<td valign="top" align="left">BD Biosciences 563363</td>
</tr>
<tr>
<td valign="top" align="left">CD38</td>
<td valign="top" align="left">PerCP/eFluor 710</td>
<td valign="top" align="left">90</td>
<td valign="top" align="left">Invitrogen 46-0381-82</td>
</tr>
<tr>
<td valign="top" align="left">CD273</td>
<td valign="top" align="left">BV786</td>
<td valign="top" align="left">TY25</td>
<td valign="top" align="left">BD Biosciences 741026</td>
</tr>
<tr>
<td valign="top" align="left">CD138</td>
<td valign="top" align="left">APC/Cyanine7</td>
<td valign="top" align="left">281-2</td>
<td valign="top" align="left">Biolegend 142530</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2d"><title>Bulk RNA sequencing and gene ontology analysis</title>
<p>SMGs from 6- and 12-month-old IL-14&#x03B1;TG and C57BL/6 mice were excised, SLGs were removed, and SMG tissue was homogenized in 1&#x2005;ml TRIzol reagent (ThermoFisher) using a handheld homogenizer. Next, 0.2&#x2005;ml of chloroform was added, and samples were vortexed for 20&#x2005;s and allowed to sit at room temperature for 15&#x2005;min. Samples were centrifuged at 10,000&#x00D7;g for 18&#x2005;min at 4&#x00B0;C and the resulting aqueous phase was passed through a genomic DNA Eliminator column from the RNeasy Plus Mini kit (Qiagen) before RNA isolation was performed per the manufacturer&#x0027;s protocol. Purified RNA concentration was calculated using a NanoDrop One spectrophotometer and 1&#x2005;&#x00B5;g of RNA was used for sequencing library preparation using the Stranded mRNA Prep kit (Illumina) at the University of Missouri Genomics Technology Core (UMGTC) Facility. Total mRNA integrity was assessed on an Agilent 5200 Fragment Analyzer before whole transcriptome sequencing to a depth of at least 50 million reads per sample was performed on a NovaSeq 6000 sequencing system (Illumina).</p>
<p>Raw FASTQ data from mouse SMGs (<italic>n</italic>&#x2009;&#x003D;&#x2009;3/genotype/timepoint) and from human minor salivary gland biopsies of SjD patients and healthy volunteers [<italic>n</italic>&#x2009;&#x003D;&#x2009;9 healthy volunteers and 35 SjD patients; accessed through the National Center for Biotechnology Information&#x0027;s Database of Genotypes and Phenotypes (dbGAP) accession phs001842.v1.p1] (<xref ref-type="bibr" rid="B20">20</xref>) were processed by the University of Missouri Bioinformatics and Analytics Core (UMBAC) Facility. Sequence read quality was assessed using FastQC and reads were filtered and trimmed using fastp (<xref ref-type="bibr" rid="B32">32</xref>), then mapped against the <italic>Mus musculus</italic> reference genome GRCm39 or the <italic>Homo sapiens</italic> reference genome GRCh38 using STAR software (<xref ref-type="bibr" rid="B33">33</xref>). Data were normalized by variance stabilizing transformation using the DESeq2 R package (<xref ref-type="bibr" rid="B34">34</xref>) and sample variance was assessed by principal component analysis (PCA). Differential gene expression analysis was performed using DESeq2, where differentially expressed genes were defined as those having a greater than 2-fold change (Log2FC&#x2009;&#x2265;&#x2009;1) and adjusted <italic>P</italic> value less than 0.05 [-Log10(padj)&#x2009;&#x2265;&#x2009;1.3]. Volcano plots of DEGs were generated using VolcaNoseR (<xref ref-type="bibr" rid="B35">35</xref>) and DEG ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway/biological process enrichment, and functional annotation analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>).</p>
</sec>
<sec id="s2e"><title>Spatial transcriptomic analysis</title>
<p>Spatial transcriptomic analysis was carried out using the poly-(dT) capture primer-based Visium v1 spatial gene expression assay from 10X Genomics (Pleasanton, CA) according to the manufacturer&#x0027;s protocols. Briefly, SMGs and SLGs were excised from 12-month-old IL-14&#x03B1;TG and C57BL/6 mice, embedded in OCT compound, snap frozen in 2-methylbutane cooled with liquid nitrogen, and cryosectioned to 10&#x2005;&#x00B5;m thickness on a Leica CM3050 cryostat. For tissue optimization, cryosections were adhered to a Visium spatial tissue optimization slide and the optimum SMG and SLG tissue permeabilization time was determined to be 18&#x2005;min. For spatial gene expression analysis, SMG and SLG cryosections were adhered to a Visium spatial gene expression slide, stained with hematoxylin and eosin, and imaged on a Zeiss Axiovert 200M inverted microscope at the UMALMC Facility. Serial tissue cryosections were also collected for immunofluorescence analysis of spatial gene expression tissues. Next, mRNA libraries were prepared and sequenced to a depth of 50,000 reads/spot on an Illumina NovaSeq 6000 sequencing system at the UMGTC Facility and FASTQ files were processed using the Space Ranger 2.0.0 pipeline at the UMBAC Facility. Spatial gene expression visualization was carried out using Loupe Browser 8.1 (10X Genomics). Unsupervised Louvain clustering using PCA embedding and a resolution of 1 was performed using BioTuring Lens, and cell cluster annotation was performed using BioTuring Talk2Data and SpatialX modules.</p>
</sec>
<sec id="s2f"><title>Statistical analysis</title>
<p>Flow cytometry data were analyzed using GraphPad Prism version 10.2.0. Data were first assessed for normality using Shapiro&#x2013;Wilk test and data with normal distribution were analyzed by one-way ANOVA followed by Sidak correction for multiple comparisons or unpaired two-tailed t test. Data that did not fit normal distribution were analyzed by Kruskal&#x2013;Wallis test followed by Dunn&#x0027;s test for multiple comparisons or Mann&#x2013;Whitney test.</p>
</sec>
<sec id="s2g" sec-type="data-availability"><title>Data availability</title>
<p>The flow cytometry data presented in this study were deposited at ImmPort Shared Data database (accession SDY3118). Raw and normalized bulk RNAseq data from IL-14&#x03B1;TG and C57BL/6 mice are provided in <xref ref-type="sec" rid="s11">Supplementary Table S2</xref>. Bulk RNAseq data from human SjD patients and healthy volunteers are available from dbGAP (accession phs001842.v1.p1). Spatial transcriptomic datasets were deposited at the National Center for Biotechnology Information&#x0027;s Gene Expression Omnibus (accession GSE298921).</p>
</sec>
</sec>
<sec id="s3" sec-type="results"><title>Results</title>
<sec id="s3a"><title>Progressive sialadenitis in Il-14&#x03B1;TG mice</title>
<p>From 6 to 18 months of age, IL-14&#x03B1;TG mice develop progressive inflammation of the submandibular and parotid glands while the sublingual glands are less affected (<xref ref-type="bibr" rid="B18">18</xref>). Hematoxylin and eosin staining of 6- and 12-month-old IL-14&#x03B1;TG mouse salivary glands revealed the presence of numerous large inflammatory foci in the SMG at 12 months of age, as compared to age-matched C57BL/6 control mouse SMG, but not in the SLG (<xref ref-type="fig" rid="F1">Figure&#x00A0;1A</xref>). These inflammatory foci were each positioned around a central blood vessel and large excretory duct (<xref ref-type="fig" rid="F1">Figure&#x00A0;1B</xref>) and stained positive for the pan-immune cell marker CD45, whereas aquaporin 5 (AQP5)<sup>&#x002B;</sup> salivary acinar cells were only present in the surrounding SMG tissue (<xref ref-type="fig" rid="F1">Figure&#x00A0;1C</xref>). Immune cell type-selective markers identified B220<sup>&#x002B;</sup> B cells and CD3<sup>&#x002B;</sup> T cells that occupied distinct areas within each focus (<xref ref-type="fig" rid="F1">Figure 1C</xref>, inset). CD11c<sup>&#x002B;</sup> dendritic cells were present throughout the focus and the surrounding SMG tissue, while CD169<sup>&#x002B;</sup> macrophages were present at the focus perimeter and throughout the surrounding SMG tissue (<xref ref-type="fig" rid="F1">Figure&#x00A0;1C</xref>, inset). Some lymphoid structures in the IL-14&#x03B1;TG SMG also stained positive for the activated B and T cell antigen GL7 (<xref ref-type="fig" rid="F1">Figure&#x00A0;1D</xref>), a marker for activated B and T cells present in germinal centers (GC) where B cells undergo antibody affinity maturation and clonal expansion (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>).</p>
<fig id="F1" position="float"><label>Figure 1</label>
<caption><p>Progressive sialadenitis in the IL-14&#x03B1;TG mouse model of Sj&#x00F6;gren&#x0027;s disease. <bold>(A)</bold> Submandibular and sublingual glands from 6- and a 12-month-old female IL-14&#x03B1;TG and C57BL/6 mice were subjected to hematoxylin and eosin staining to assess glandular inflammation; scale bar&#x2009;&#x003D;&#x2009;1&#x2005;mm. <bold>(B)</bold> Immune cell focus surrounding blood vessels and excretory ducts in a 12-month-old IL-14&#x03B1;TG mouse SMG; scale bar&#x2009;&#x003D;&#x2009;100&#x2005;&#x00B5;m. <bold>(C)</bold> Twelve-month-old and <bold>(D)</bold> 18-month-old female IL-14&#x03B1;TG mouse SMG and SLG cryosections were subjected to immunofluorescence staining using antibodies against aquaporin 5 (AQP5) acinar cell marker, CD45 pan-immune cell marker, B220 B cell marker, CD3 T cell marker, CD169 macrophage marker, CD11c dendritic cell marker or GL7 germinal center marker with DAPI nuclear counterstain; scale bars&#x2009;&#x003D;&#x2009;1&#x2005;mm and 100&#x2005;&#x00B5;m (inset).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g001.tif"><alt-text content-type="machine-generated">Panel A displays histological comparisons of tissue samples at six and twelve months from IL-14&#x03B1;TG and C57BL/6 mice. Panel B shows a detailed close-up of a stained tissue section highlighting cellular structures. Panel C features immunofluorescence labeling, showcasing diverse cell types like B220&#x002B; B cells, CD3&#x002B; T cells, macrophages, and more within a tissue sample. Panel D illustrates another immunofluorescence image, focusing on CD3 and B220 markers, with detailed insets emphasizing specific stained areas.</alt-text>
</graphic>
</fig>
<p>Because the sublingual glands lacked immune cell foci and are the least affected salivary glands in SjD patients (<xref ref-type="bibr" rid="B40">40</xref>), flow cytometry was performed on immune cells isolated from SMGs at the 12-month time point and the results reflected histological findings, where a significant increase in CD45<sup>&#x002B;</sup> immune cells was observed in IL-14&#x03B1;TG mice as compared to age-matched C57BL/6 mice (<xref ref-type="fig" rid="F2">Figure&#x00A0;2A</xref>). Previous studies identified alterations in innate B1 and conventional B2 cell subpopulations in IL-14&#x03B1;TG vs. littermate control mice (<xref ref-type="bibr" rid="B16">16</xref>); therefore, we compared B lymphocyte subpopulations and initially stratified cells based on CD19, B220 and CD5 expression. B1 cells, which have long been implicated in the development of autoimmunity and production of autoantibodies (<xref ref-type="bibr" rid="B41">41</xref>), were identified in both IL-14&#x03B1;TG and C57BL/6 mouse SMGs; however, no significant differences were observed between genotypes with regards to either B1a (CD19<sup>&#x002B;</sup>, B220<sup>&#x2212;</sup>, CD5<sup>&#x002B;</sup>) or B1b (CD19<sup>&#x002B;</sup>, B220<sup>&#x2212;</sup>, CD5<sup>&#x2212;</sup>) cell subsets (<xref ref-type="fig" rid="F2">Figure&#x00A0;2B</xref>). In the conventional B2 cell compartment (CD19<sup>&#x002B;</sup>, B220<sup>&#x002B;</sup>), cell fate decisions determining differentiation into recirculating short-lived follicular B cells (CD23<sup>&#x002B;</sup>) or long-lived static marginal zone (MZ) B cells (CD21/35<sup>&#x002B;</sup>) are dictated by the strength of B cell receptor (BCR) signaling (<xref ref-type="bibr" rid="B42">42</xref>), and both follicular and MZ B cells were identified in IL-14&#x03B1;TG and C57BL/6 mouse SMGs (<xref ref-type="fig" rid="F2">Figure&#x00A0;2C</xref>). Follicular B cells represented &#x223C;1&#x0025; of total immune cells in both genotypes and levels were not significantly different; however, the proportion of MZ B cells was significantly increased 5-fold in IL-14&#x03B1;TG mouse SMG as compared to controls (<xref ref-type="fig" rid="F2">Figure&#x00A0;2C</xref>). GC B cells (GL7<sup>&#x002B;</sup>) were present in the IL-14&#x03B1;TG mouse SMG, confirming observations of GL7 immunofluorescence staining (<xref ref-type="fig" rid="F1">Figure&#x00A0;1D</xref>), and we observed similar levels of GL7<sup>&#x002B;</sup> B cells in C57BL/6 mouse control SMGs (<xref ref-type="fig" rid="F2">Figure&#x00A0;2C</xref>). In both genotypes, long-lived memory B cells (CD38<sup>&#x002B;</sup>, CD273<sup>&#x002B;</sup>) represented the least abundant B cell population (&#x223C;0.6&#x0025;; <xref ref-type="fig" rid="F2">Figure 2C</xref>) and antibody producing plasma cells (CD19<sup>&#x2212;</sup>, CD138<sup>&#x002B;</sup>) were the most abundant population, representing 30&#x0025;&#x2013;35&#x0025; of all CD45<sup>&#x002B;</sup> SMG-infiltrating immune cells (<xref ref-type="fig" rid="F2">Figure&#x00A0;2D</xref>). However, no statistical differences between genotypes were observed in either population.</p>
<fig id="F2" position="float"><label>Figure 2</label>
<caption><p>Flow cytometry analysis of IL-14&#x03B1;TG and C57BL/6 mouse SMG-infiltrating immune cells. SMGs from 12-month-old IL-14&#x03B1;TG and C57BL/6 mice were enzymatically dispersed, stained with either a B or T cell type-specific antibody panel and analyzed by flow cytometry on a Cytek Aurora spectral analyzer. <bold>(A)</bold> Total CD45<sup>&#x002B;</sup> immune cells, <bold>(B&#x2013;D)</bold> B cell subpopulations and <bold>(E&#x2013;H)</bold> T cell subpopulations were quantified, and data are presented as means&#x2009;&#x00B1;&#x2009;S.D., where &#x002A; and &#x002A;&#x002A; indicate <italic>P</italic>&#x2009;&#x003C;&#x2009;0.05 and 0.01, respectively, for <italic>n</italic>&#x2009;&#x003D;&#x2009;5 mice per group.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g002.tif"><alt-text content-type="machine-generated">Graphs compare cell populations in the submandibular glands of IL-14&#x03B1;TG and C57BL/6 mice. Panel A shows a higher number of CD45&#x002B; cells in IL-14&#x03B1;TG. Panels B to H detail various B cell, T cell, and plasma cell subpopulations, highlighting significant differences, such as increased marginal zone B cells in IL-14&#x03B1;TG (Panel C). Each bar represents mean values with error bars.</alt-text>
</graphic>
</fig>
<p>We next examined T cell subpopulations in the SMG and found no significant differences in the proportion of total CD3<sup>&#x002B;</sup> T cells (<xref ref-type="fig" rid="F2">Figure&#x00A0;2E</xref>) or CD4<sup>&#x002B;</sup> T helper (TH) cells (<xref ref-type="fig" rid="F2">Figure&#x00A0;2F</xref>) between IL-14&#x03B1;TG and C57BL/6 mice. Further analysis of CD4<sup>&#x002B;</sup> TH subsets, including TH1 (CXCR3<sup>&#x002B;</sup>), TH2 (GATA3<sup>&#x002B;</sup>), TH17 (ROR&#x03B3;t<sup>&#x002B;</sup>) and TREG (FoxP3<sup>&#x002B;</sup>, CD25<sup>&#x002B;</sup>) cells, did not reveal significant differences between IL-14&#x03B1;TG and C57BL/6 mouse SMG (<xref ref-type="fig" rid="F2">Figure&#x00A0;2G</xref>). In both genotypes, TH17 cells made up the highest proportion of total CD45<sup>&#x002B;</sup> immune cells among all TH cell subsets (&#x223C;4&#x0025;), whereas TH2 cells made up the lowest proportion (&#x003C; 0.1&#x0025;). Additionally, all SMG-infiltrating TREG cells in both genotypes were found to express the activation marker CD69 that enhances the immunomodulatory capacity of these cells (<xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>) (<xref ref-type="bibr" rid="B43">43</xref>). In contrast to the CD4<sup>&#x002B;</sup> TH cell populations, we observed a significant increase in the proportion of CD8<sup>&#x002B;</sup> T cells in C57BL/6 as compared to IL-14&#x03B1;TG mouse SMG (<xref ref-type="fig" rid="F2">Figure&#x00A0;2F</xref>). Within the CD8<sup>&#x002B;</sup> T cell compartment, we further analyzed the proportion and activation state of the non-recirculating long-lived T resident memory (TRM) cells (<xref ref-type="bibr" rid="B44">44</xref>) using the TRM cell marker CD69 and the exhausted T cell marker programmed death-1 (PD-1), respectively, but found no significant differences in TRM levels nor exhaustion state between genotypes (<xref ref-type="fig" rid="F2">Figure&#x00A0;2H</xref>).</p>
</sec>
<sec id="s3b"><title>Common and unique transcriptomic changes in Il-14&#x03B1;TG mouse and SjD patient salivary glands</title>
<p>Bulk RNAseq analysis of SMGs from 6-month-old and 12-month-old IL-14&#x03B1;TG and C57BL/6 mice identified upregulated and downregulated DEGs in multiple transcriptome comparisons. In the mouse SMG, dramatic changes in the transcriptomic landscape occurred during aging, where the 12-month-old vs. 6-month-old IL-14&#x03B1;TG mouse SMG comparison identified 1,653 total DEGs and 12-month-old vs. 6-month-old C57BL/6 mouse SMG comparison identified 508 DEGs (<xref ref-type="table" rid="T2">Table&#x00A0;2</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S4</xref>). Comparison of age-matched IL-14&#x03B1;TG and C57BL/6 mouse SMGs at the 6-month and 12-month timepoints yielded 25 DEGs and 406 DEGs, respectively. We further analyzed human DEGs from bulk RNAseq analysis of minor salivary gland (MSG) biopsies from SjD patients and healthy volunteers (accessed through dbGAP accession phs001842.v1.p1) (<xref ref-type="bibr" rid="B20">20</xref>) and found 1,339 DEGs (<xref ref-type="table" rid="T2">Table&#x00A0;2</xref>). Principal component analysis of mouse SMG RNAseq data showed that IL-14&#x03B1;TG and C57BL/6 mouse SMGs grouped tightly at the 6-month time point, but diverged at the 12-month time point, with PC1 accounting for 79&#x0025; of variance between samples compared to 7&#x0025; of the variance for PC2 (<xref ref-type="fig" rid="F3">Figure&#x00A0;3A</xref>). PCA of human minor salivary gland samples demonstrated a similar magnitude of variance across both PC1 and PC2 axes and diffuse grouping (<xref ref-type="fig" rid="F3">Figure&#x00A0;3B</xref>). Volcano plots of DEGs in 12-month-old IL-14&#x03B1;TG vs. C57BL/6 mouse SMGs (<xref ref-type="fig" rid="F3">Figure&#x00A0;3C</xref>) and SjD patient vs. healthy volunteer (HV) MSGs (<xref ref-type="fig" rid="F3">Figure&#x00A0;3D</xref>) show the significance (-Log<sub>10</sub> padj) and magnitude (Log<sub>2</sub>-fold change) of up- and downregulated DEGs, with annotated dots denoting the top 10 DEGs based on Manhattan distance from origin. Gene ontology analysis of all upregulated DEGs revealed a significant enrichment of KEGG pathways and biological processes associated with immune responses, autoimmunity, and viral infection with substantial overlap noted between IL-14&#x03B1;TG SMG (<xref ref-type="fig" rid="F3">Figure&#x00A0;3E</xref>) and SjD patient MSG biopsies (<xref ref-type="fig" rid="F3">Figure&#x00A0;3F</xref>). In total, 66 biological processes and 22 KEGG pathways were significantly enriched [False Discovery Rate (FDR)&#x2009;&#x003C;&#x2009;0.05] in mouse SMG and 169 biological processes (BP) and 68 KEGG pathways were significantly enriched in human MSG (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). Gene ontology analysis of downregulated DEGs did not identify any significantly enriched pathways or processes. Interestingly, gene ontology analysis of DEGs associated with aging (<italic>i.e.</italic>, 12-month vs. 6-month) in either C57BL/6 or IL-14&#x03B1;TG mouse genotypes showed enrichment of inflammatory KEGG pathways and biological processes that mirrored those seen in diseased vs. control samples (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>), corroborating recent reports on the presence of chronic inflammatory pathologies in aged C57BL/6 mouse SMG and lacrimal glands (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B45">45</xref>).</p>
<table-wrap id="T2" position="float"><label>Table 2</label>
<caption><p>Differentially expressed genes identified in whole tissue RNAseq analysis of 6-month-old and 12-month-old IL-14&#x03B1;TG and C57BL/6 mouse SMGs and minor salivary gland biopsies from Sj&#x00F6;gren&#x0027;s disease patients and healthy volunteers.</p></caption>
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th valign="top" align="left">Transcriptome comparison</th>
<th valign="top" align="center">Upregulated DEGs</th>
<th valign="top" align="center">Downregulated DEGs</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">12 mo C57BL/6 vs. 6 mo C57BL/6</td>
<td valign="top" align="center">503</td>
<td valign="top" align="center">5</td>
</tr>
<tr>
<td valign="top" align="left">12 mo IL-14&#x03B1;TG vs. 6 mo IL-14&#x03B1;TG</td>
<td valign="top" align="center">1,627</td>
<td valign="top" align="center">26</td>
</tr>
<tr>
<td valign="top" align="left">12 mo and 6 mo IL-14&#x03B1;TG vs. 12 mo and 6 mo C57BL/6</td>
<td valign="top" align="center">10</td>
<td valign="top" align="center">12</td>
</tr>
<tr>
<td valign="top" align="left">6 mo IL-14&#x03B1;TG vs. C57BL/6</td>
<td valign="top" align="center">14</td>
<td valign="top" align="center">11</td>
</tr>
<tr>
<td valign="top" align="left">12 mo IL-14&#x03B1;TG vs. C57BL/6</td>
<td valign="top" align="center">383</td>
<td valign="top" align="center">23</td>
</tr>
<tr>
<td valign="top" align="left">Sj&#x00F6;gren&#x0027;s disease vs. healthy volunteers</td>
<td valign="top" align="center">1,272</td>
<td valign="top" align="center">67</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F3" position="float"><label>Figure 3</label>
<caption><p>Comparison of differentially expressed genes from IL-14&#x03B1;TG mouse submandibular glands and human SjD minor salivary glands. RNA prepared from 6- and 12-month-old IL-14&#x03B1;TG and C57BL/6 SMGs was subjected to RNAseq analysis. Previously performed RNAseq analysis of SjD patient and healthy volunteer MSG was accessed through dbGAP accession phs001842.v1.p1. Up- and downregulated DEGs were identified and analyzed by <bold>(A,B)</bold> principal component analysis, <bold>(C,D)</bold> DEG volcano plots and <bold>(E,F)</bold> DAVID gene ontology analysis, where <bold>(A,C,E)</bold> are results from IL-14&#x03B1;TG vs. C57BL/6 mouse SMGs (<italic>n</italic>&#x2009;&#x003D;&#x2009;3/timepoint/genotype) and <bold>(B,D,F)</bold> are results from SjD patient vs. healthy volunteer MSG biopsies (<italic>n</italic>&#x2009;&#x003D;&#x2009;35 SjD patients and 9 healthy volunteers).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g003.tif"><alt-text content-type="machine-generated">Six-panel figure displaying various data visualizations related to differential gene expression (DEG) and gene ontology analysis: A. Scatter plot showing principal component analysis (PCA) of IL-14&#x03B1;TG and C57BL/6 mice at 6 and 12 months. B. Scatter plot of PCA comparing SjD patients and healthy volunteers. C. Volcano plot showing DEGs in IL-14&#x03B1;TG vs C57BL/6 at 12 months with 23 downregulated and 383 upregulated genes. D. Volcano plot for DEGs in SjD vs healthy volunteers with 67 downregulated and 1272 upregulated genes. E and F. Bar graphs illustrating upregulated DEG gene ontology analysis for 12-month IL-14&#x03B1;TG and SjD, detailing KEGG pathways and biological processes with fold enrichment and false discovery rate (FDR).</alt-text>
</graphic>
</fig>
<p>Next, we compared DEGs in 12-month-old vs. 6-month-old IL-14&#x03B1;TG mouse SMGs and 12-month-old vs. 6-month-old C57BL/6 mouse SMGs and removed genes that were differentially expressed in both genotypes, reasoning that these genes would be associated with aging and the unique IL-14&#x03B1;TG mouse DEGs would be disease model-specific. In total, 457 DEGs were common between both genotypes, leaving 1,196 DEGs unique to the IL-14&#x03B1;TG mouse SMG disease model (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). When grouped by gene biotype, protein coding genes made up the majority of IL-14&#x03B1;TG mouse SMG unique DEGs (&#x223C;79&#x0025;) followed by long non-coding RNA (lncRNA) and immunoglobulin genes (<xref ref-type="fig" rid="F4">Figure&#x00A0;4A</xref>). The top 10 unique IL-14&#x03B1;TG DEGs based on Manhattan distance were identified by volcano plot and included the IgH constant and variable chain genes <italic>Ighg3</italic> and <italic>Ighv1-64</italic> (homologous to human <italic>Ighv1-24</italic>), the B cell genes <italic>Cd19</italic> and <italic>Cd79a</italic>, the T cell genes <italic>Trac</italic> and <italic>Cd8a</italic>, the IgM receptor gene <italic>Fcmr</italic>, and the tumor necrosis factor family member lymphotoxin-&#x03B2; gene (<italic>Ltb</italic>) that functions in GC formation (<xref ref-type="bibr" rid="B46">46</xref>), all of which are DEGs in SjD vs. HV MSGs (<xref ref-type="fig" rid="F4">Figure&#x00A0;4B</xref> and <xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). Also identified was the upregulation of the lncRNA gene <italic>Gm15987</italic> and <italic>Fam169b</italic> and the downregulation of the transcription factor <italic>Dbp</italic>, which were not identified as DEGs in SjD vs. HV MSGs. Gene ontology analysis of upregulated unique IL-14&#x03B1;TG mouse SMG DEGs identified 215 significantly enriched biological processes and 55 KEGG pathways in total, with 81 biological processes and 44 KEGG pathways shared in IL-14&#x03B1;TG mouse and human SjD samples (<xref ref-type="fig" rid="F4">Figure&#x00A0;4C</xref> and <xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). In contrast to human and mouse diseased vs. control transcriptome comparisons, the unique IL-14&#x03B1;TG mouse SMG downregulated DEGs showed significant enrichment of the circadian rhythm and rhythmic process KEGG pathway and biological processes (<xref ref-type="fig" rid="F4">Figure&#x00A0;4D</xref>).</p>
<fig id="F4" position="float"><label>Figure 4</label>
<caption><p>Unique differentially expressed genes in IL-14&#x03B1;TG mouse submandibular glands. DEG lists from 12-month-old vs. 6-month-old IL-14&#x03B1;TG and 12-month-old vs. 6-month-old C57BL/6 mouse SMGs were compared and genes that were differentially expressed with age in both genotypes were removed to generate a list of DEGs unique to IL-14&#x03B1;TG SMG. <bold>(A)</bold> Venn diagram of shared and unique genes differentially expressed with age and pie chart of IL-14&#x03B1;TG unique DEG biotype; TEC,To be Experimentally Confirmed. <bold>(B)</bold> Volcano plot of unique DEGs in IL-14&#x03B1;TG mouse SMG. <bold>(C)</bold> DAVID gene ontology analysis of upregulated unique IL-14&#x03B1;TG mouse SMG DEGs to identify enriched KEGG pathways and biological processes, with Venn diagrams denoting shared and unique signaling pathway enrichment between IL-14&#x03B1;TG mouse SMG and human SjD MSG biopsies. <bold>(D)</bold> DAVID gene ontology analysis of downregulated unique IL-14&#x03B1;TG mouse SMG DEGs.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g004.tif"><alt-text content-type="machine-generated">Research data visualizations on IL-14&#x03B1;TG disease progression. (A) Venn diagram and pie chart of differentially expressed genes (DEGs) comparing IL-14&#x03B1;TG and C57BL/6. (B) Volcano plot showing 1,176 upregulated and 20 downregulated DEGs. (C) KEGG pathways and biological processes for upregulated DEGs, with bar graphs indicating fold enrichment and false discovery rate (FDR). Venn diagrams of IL-14&#x03B1;TG and SjD DEGs for KEGG pathways and biological processes. (D) Bar graphs of downregulated DEGs&#x0027; gene ontology analysis, highlighting fold enrichment and FDR for pathways related to the circadian rhythm.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3c"><title>Spatial transcriptomic analysis revealed tissue localization of immune cell gene markers</title>
<p>Results from spatial transcriptomic analysis validated immune cell marker localization observed by immunofluorescence analysis and provided insights on tissue localization of DEGs identified by RNAseq analysis. In 12-month-old IL-14&#x03B1;TG mouse SMG and SLG, localization of mRNA encoding the salivary acinar cell water channel aquaporin 5 (<italic>Aqp5</italic>) and the pan-immune cell marker CD45 (<italic>Ptprc</italic>) (<xref ref-type="fig" rid="F5">Figure&#x00A0;5</xref>) largely mirrored observations from immunofluorescence analysis of a serial IL-14&#x03B1;TG mouse salivary gland section using anti-AQP5 and anti-CD45 antibodies (<xref ref-type="fig" rid="F1">Figure&#x00A0;1C</xref>). <italic>Aqp5</italic> and <italic>Ptprc</italic> expression delineated salivary acinar tissue and immune cell foci, respectively. However, <italic>Aqp5</italic> expression was also observed within the immune cell foci and immune cells did not ubiquitously express <italic>Ptprc</italic> in contrast to immunofluorescence observations. The <italic>Aqp5</italic> localization in immune cells may reflect the presence of acinar cells localized above or below the focal plane during confocal microscopy and the lack of <italic>Ptprc</italic> expression in immune cells may be due to low-level mRNA expression that was below the sequencing threshold. Visium v1 uses a grid of barcoded probe capture areas 55&#x2005;&#x00B5;m in diameter that bind polyadenylated mRNA, resulting in each cluster being a representative mRNA pool from multiple cell types in the capture area. When examining localization of immune cell marker genes, many immune cell clusters expressed gene markers for multiple cell types. Because the B cell marker antibody B220 (CD45R) detects a splice variant of <italic>Ptprc</italic>, we instead used <italic>CD19</italic> expression to identify B cells and <italic>CD3e</italic> expression to identify T cells and observed distinct expression patterns within each focus (<xref ref-type="fig" rid="F5">Figure 5</xref>). Localization of <italic>Siglec1</italic> (CD169) and <italic>Itgax</italic> (CD11c) resembled immunofluorescence analysis, where CD169<sup>&#x002B;</sup> macrophages localized to the focus periphery and CD11c<sup>&#x002B;</sup> dendritic cells were present throughout the focus (<xref ref-type="fig" rid="F1">Figure 1C</xref>). The GL7 antibody used for the detection of activated B and T cells in germinal centers binds a sialic acid glycan (<xref ref-type="bibr" rid="B47">47</xref>), so we instead observed the localization of <italic>Ltb</italic> and <italic>Cxcl13</italic> that are essential, but not exclusive, markers for GC development (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B48">48</xref>) and found robust expression of both genes in IL-14&#x03B1;TG mouse salivary gland immune cell foci (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p>
<fig id="F5" position="float"><label>Figure 5</label>
<caption><p>Spatially resolved gene marker expression in IL-14&#x03B1;TG mouse salivary glands using spatial transcriptomic analysis. Fresh frozen SMG and SLG cryosections from a 12-month-old female IL-14&#x03B1;TG mouse were adhered to a barcoded Visium spatial gene expression slide, stained with hematoxylin and eosin, visualized on a Zeiss Axiovert 200M inverted microscope, and then subjected to RNAseq analysis. Color-coded expression of individual gene markers [Log2(counts/capture area)] in barcoded mRNA capture areas was overlaid on the tissue image using Loupe browser 8.1 software. Scale bar&#x2009;&#x003D;&#x2009;1&#x2005;mm and 100&#x2005;&#x00B5;m (inset).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g005.tif"><alt-text content-type="machine-generated">Histological images and heat maps of tissue samples stained with Hematoxylin and Eosin. The images display various markers: Ptprc (CD45), Aqp5 (Aquaporin 5), CD19, CD3e, Siglec1 (CD169), Itgax (CD11c), Ltb, and Cxcl13. Each marker is highlighted with a color gradient indicating expression levels, with insets showing detailed views.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3d"><title>Clustering of spatial transcriptomic capture areas revealed cell type enrichment and localization within salivary gland tissue</title>
<p>We utilized BioTuring software to perform clustering of mRNA capture areas and identify areas spatially enriched in specific cell types (<xref ref-type="fig" rid="F6">Figure&#x00A0;6</xref>). Unsupervised clustering of capture areas identified 9 distinct cell clusters for the 12-month-old IL-14&#x03B1;TG mouse SMG and SLG and 7 clusters for the C57BL/6 mouse salivary glands (data not shown). However, two IL-14&#x03B1;TG and three C57BL/6 mouse clusters were enriched in salivary gland acinar genes and appeared otherwise indistinguishable. Therefore, these acinar-enriched clusters were combined for each sample and the uniform manifold approximation and projection (UMAP) dimensionality reduction revealed a total of 8 IL-14&#x03B1;TG (<xref ref-type="fig" rid="F6">Figure&#x00A0;6A</xref>) and 5 C57BL/6 (<xref ref-type="fig" rid="F6">Figure&#x00A0;6B</xref>) mouse salivary gland cell clusters. Color-coded, cell type-enriched clusters were overlayed on the hematoxylin and eosin-stained salivary gland sections (<xref ref-type="fig" rid="F6">Figures&#x00A0;6C,D</xref>) to reveal spatially resolved cell type enrichment (<xref ref-type="fig" rid="F6">Figures&#x00A0;6E,F</xref>). Due to the low resolution of Visium v1 resulting from 55&#x2005;&#x00B5;m diameter probe capture areas, identification of individual cell types was not possible, and cluster annotations indicate enrichment signatures for the indicated cell types rather than homogeneous cell populations. For cluster annotation, we first utilized the cluster-defining genes from a previously published mouse SMG scRNAseq analysis (<xref ref-type="bibr" rid="B25">25</xref>). However, many of the cell type gene markers used for annotation, such as acinar cell secretoglobins (<italic>i.e.</italic>, <italic>Scgb2b26, Scgb1b27</italic> and <italic>Scgb2b27),</italic> were ubiquitously expressed across all clusters (<xref ref-type="sec" rid="s11">Supplementary Figure S5</xref>). Furthermore, the scRNAseq dataset lacked representative sublingual gland, B cell, T cell and neural cell populations. Instead, clusters were annotated using published mouse salivary and lacrimal gland scRNAseq and spatial transcriptomic datasets (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B49">49</xref>) and the cell type prediction tool of BioTuring SpatialX that uses a reference database of all annotated scRNAseq datasets in the Talk2Data module. In both IL-14&#x03B1;TG and C57BL/6 mouse tissues, sublingual glands formed a single cluster marked by <italic>Dcpp1-3</italic>, <italic>A2ml1</italic> and <italic>Syt7</italic>, whereas submandibular glands contained multiple cell clusters enriched in salivary epithelial cell markers and/or immune cell markers (<xref ref-type="fig" rid="F6">Figures&#x00A0;6G,H</xref>). SMG acinar cell markers included <italic>Lpo</italic>, <italic>Slc12a2</italic> and <italic>Nupr1</italic> while SMG duct cell markers included <italic>Crisp3</italic> and various kallikrein serine proteases (<italic>i.e.</italic>, <italic>Klk1b26</italic>, <italic>Klk1b5</italic> and <italic>Klk1b11</italic>). In the SMG of both genotypes, a population of histologically epithelial cell clusters located near the sublingual gland were enriched in <italic>Bpifa2</italic>, <italic>Dcpp1</italic>-3 and <italic>Muc19</italic> compared to SMG acinar- and SMG duct-enriched clusters and these likely represent <italic>Bpifa2</italic><sup>&#x002B;</sup> serous-like acinar cells previously identified in the adult mouse SMG (<xref ref-type="bibr" rid="B25">25</xref>). In the C57BL/6 mouse SMG, one cell cluster was enriched in immune cells including the B cell markers <italic>Jchain, CD79A</italic> and <italic>CD79B</italic> and the macrophage markers <italic>C1Qa/b</italic>, <italic>Tyrobp</italic> and <italic>H2-Aa</italic>, with lower expression of the T cell marker <italic>CD3e</italic>. In the IL-14&#x03B1;TG mouse SMG, 3 cell clusters were enriched in immune cell gene markers including the B cell-enriched cluster found in C57BL/6 mouse SMG, an activated B and T cell cluster with increased expression of <italic>CD3e</italic> and the GC markers <italic>Cxcl13</italic> and <italic>Ltb</italic>, and a mixed immune/epithelial cell cluster located at the periphery of the immune cell foci. The latter cell cluster appears to be SMG acinar and ductal cells histologically, but also expresses higher levels of immune cell markers compared to SMG acinar-enriched and duct-enriched cell clusters. Lastly, cell clusters located near the main excretory duct in the IL-14&#x03B1;TG mouse SMG expressed the neuronal microtubule component gene <italic>Tubb3</italic>, the voltage-gated potassium channel-interacting protein gene <italic>Kcnip4</italic>, and the dendritic notch signaling regulator gene <italic>Dner</italic>, thusly defining a population of neural cells that likely represent the SMG-innervating facial nerve that is closely associated with the Wharton&#x0027;s excretory duct and blood vessels that vascularize the SMG (<xref ref-type="bibr" rid="B50">50</xref>).</p>
<fig id="F6" position="float"><label>Figure 6</label>
<caption><p>Spatial transcriptomic analysis and cell clustering of IL-14&#x03B1;TG and C57BL/6 mouse salivary glands. RNAseq analyses of barcoded Visium spatial mRNA capture areas from 12-month-old female IL-14&#x03B1;TG or C57BL/6 mouse SMG and SLG were subjected to unsupervised Louvain clustering and visualization using Bioturing software. <bold>(A,B)</bold> UMAP and color-coded cell cluster identification, <bold>(C,D)</bold> hematoxylin and eosin (H&#x0026;E)-stained tissue images, <bold>(E,F)</bold> cell cluster spatial localization overlay on H&#x0026;E tissue images, and <bold>(G,H)</bold> dot plot of cell cluster-defining gene markers in <bold>(A,C,E)</bold> IL-14&#x03B1;TG and <bold>(B,D,F)</bold> C57BL/6 mouse SMG and SLG. Scale bar&#x2009;&#x003D;&#x2009;1&#x2005;mm.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g006.tif"><alt-text content-type="machine-generated">The image comprises multiple panels showing cellular analysis and tissue samples in mice. Panels A and B present scatter plots of cell types with color-coded legends. Panels C and D display unlabeled tissue sections, while Panels E and F illustrate corresponding sections with overlaid color-coded annotation. Panels G and H feature dot plots displaying expression levels of different genes across specific cell types, with varying dot sizes and colors indicating expression intensity and percentage.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3e"><title>Spatial localization and cell cluster enrichment of gene markers for immune cell subtypes and DEGs</title>
<p>Flow cytometry results indicated that plasma cells represented the largest population of CD45<sup>&#x002B;</sup> immune cells in both IL-14&#x03B1;TG and C57BL/6 mouse SMG (<xref ref-type="fig" rid="F2">Figure 2D</xref>) and these cells abundantly express <italic>Jchain</italic>, a linker polypeptide for the multimeric assembly of IgM and IgA from antibody-secreting cells (<xref ref-type="bibr" rid="B51">51</xref>). Spatial transcriptomic analysis showed high <italic>Jchain</italic> expression localized in and around the SMG immune cell foci of both genotypes and violin plots demonstrated enriched expression in activated B and T cell, B cell-enriched, and mixed immune/epithelium cell clusters, with lower expression in non-immune cell clusters (<xref ref-type="fig" rid="F7">Figure&#x00A0;7A</xref>). In the IL-14&#x03B1;TG mouse salivary gland, higher level <italic>Jchain</italic> expression was observed at the periphery of immune cell foci, with the core showing lower or no expression. The proportion of marginal zone B cells was significantly increased in IL-14&#x03B1;TG, as compared to C57BL/6 mouse SMG (<xref ref-type="fig" rid="F2">Figure 2C</xref>), and MZ B cells abundantly express <italic>Mzb1</italic>, which encodes the endoplasmic reticulum protein pERp1 that functions in Ca<sup>2&#x002B;</sup> homeostasis and immunoglobulin assembly (<xref ref-type="bibr" rid="B52">52</xref>). In the SMG, low levels of <italic>Mzb1</italic> were expressed in IL-14&#x03B1;TG mice with spatial localization in immune cell-enriched clusters, but <italic>Mzb1</italic> was undetectable in C57BL/6 mice (<xref ref-type="fig" rid="F7">Figure&#x00A0;7B</xref>). Similarly, mRNA capture areas co-expressing the MZ B cell markers <italic>CD19</italic> and <italic>Cr2</italic> (<italic>i.e.</italic>, complement receptor 2; CD21/35) were identified in IL-14&#x03B1;TG mouse SMG, but were absent in C57BL/6 mouse SMG (<xref ref-type="sec" rid="s11">Supplementary Figure S6</xref>). While the proportion of CD8<sup>&#x002B;</sup> T cells was significantly increased in C57BL/6 mouse SMG, as compared to IL-14&#x03B1;TG mice (<xref ref-type="fig" rid="F2">Figure 2F</xref>), absolute expression of the CD8 alpha subunit gene <italic>CD8a</italic> was greater in IL-14&#x03B1;TG mouse SMG and violin plots show localization primarily in the activated B and T cell cluster with low expression in all other cell clusters (<xref ref-type="fig" rid="F7">Figure&#x00A0;7C</xref>). All four immune cell marker genes <italic>Jchain</italic>, <italic>Mzb1</italic>, <italic>Cr2</italic>, and <italic>CD8a</italic> were upregulated DEGs in RNAseq analyses of 12-month-old IL-14&#x03B1;TG vs. C57BL/6 mouse SMG (<xref ref-type="fig" rid="F7">Figure&#x00A0;7D</xref>) and <italic>Mzb1</italic>, <italic>Cr2</italic> and <italic>CD8a</italic> were upregulated DEGs in human SjD vs. healthy volunteer MSG (<xref ref-type="fig" rid="F7">Figure&#x00A0;7E</xref>).</p>
<fig id="F7" position="float"><label>Figure 7</label>
<caption><p>Immune cell gene marker expression, localization, and cell cluster distribution in IL-14&#x03B1;TG and C57BL/6 mouse salivary glands. Color-coded expression [Log2(counts/capture area)] and cell cluster distribution violin plots of <bold>(A)</bold> <italic>Jchain</italic> (plasma cell marker), <bold>(B)</bold> <italic>Mzb1</italic> (MZ B cell marker) and <bold>(C)</bold> <italic>CD8a</italic> (CD8 T cell marker) in 12-month-old IL-14&#x03B1;TG and C57BL/6 mouse SMG and SLG; scale bar&#x2009;&#x003D;&#x2009;1&#x2005;mm. Volcano plots denoting immune cell marker DEGs identified by RNAseq analysis of <bold>(D)</bold> 12-month-old IL-14&#x03B1;TG vs. C57BL/6 mouse SMG and <bold>(E)</bold> SjD patient vs. healthy volunteer MSG.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g007.tif"><alt-text content-type="machine-generated">Panel A shows expression of Jchain in mouse salivary glands, with differences noted between IL-14&#x03B1;TG and C57BL/6 strains. Panel B presents Mzb1 expression, displaying minimal differences. Panel C illustrates CD8a expression, with notable activation in B and T cells. Panel D is a scatter plot comparing differentially expressed genes (DEGs) between IL-14&#x03B1;TG and C57BL/6 mice at 12 months, highlighting genes like CD8a and Jchain. Panel E shows DEGs in Sj&#x00F6;gren&#x0027;s Syndrome patients vs. healthy volunteers, indicating significant upregulation of genes such as Mzb1 and CD8a.</alt-text>
</graphic>
</fig>
<p>Flow cytometry analysis identified GL7<sup>&#x002B;</sup> GC B cells in both 12-month-old IL-14&#x03B1;TG and C57BL/6 mouse SMG (<xref ref-type="fig" rid="F2">Figure 2C</xref>) and we observed expression of the GC gene markers <italic>Ltb</italic> and <italic>Cxcl13</italic> in immune cell foci in IL-14&#x03B1;TG mouse SMG (<xref ref-type="fig" rid="F5">Figure 5</xref>). Spatial transcriptomic analysis revealed abundant expression of <italic>Ltb</italic> in IL-14&#x03B1;TG compared to C57BL/6 mouse SMG that was primarily localized to activated B and T cell and B cell-enriched clusters, with lower expression observed in mixed immune/epithelium, neural cell-enriched and sublingual gland clusters (<xref ref-type="fig" rid="F8">Figure&#x00A0;8A</xref>). Similarly, <italic>Cxcl13</italic> was more abundantly expressed in IL-14&#x03B1;TG compared to C57BL/6 mouse SMG and expression was almost exclusively localized to activated B and T cell and B cell-enriched clusters (<xref ref-type="fig" rid="F8">Figure&#x00A0;8B</xref>). RNAseq analysis of 12-month-old IL-14&#x03B1;TG vs. C57BL/6 mouse SMG indicated that <italic>Glycam1,</italic> a marker for high endothelial venules (HEVs), was one of the most highly upregulated DEGs based on Manhattan distance from origin (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Whereas GCs serve as sites for B cell maturation and clonal expansion, HEVs support the extravasation of lymphocytes from the blood stream into inflamed tissues (<xref ref-type="bibr" rid="B53">53</xref>). <italic>Glycam1</italic> was abundantly expressed in the activated B and T cell and B cell-enriched clusters of IL-14&#x03B1;TG mouse SMG, but was nearly undetectable in C57BL/6 mouse SMG (<xref ref-type="fig" rid="F8">Figure&#x00A0;8C</xref>). Similarly, <italic>Ccl21a</italic> encoding the potent lymphocyte chemokine expressed in HEV endothelial cells (<xref ref-type="bibr" rid="B54">54</xref>), was highly expressed in activated B and T cell and B cell-enriched clusters of IL-14&#x03B1;TG mouse SMG, with expression also observed in the neural cell-enriched cluster (<xref ref-type="fig" rid="F8">Figure&#x00A0;8D</xref>). RNAseq analysis further identified <italic>Ltb</italic>, <italic>Cxcl13</italic> and <italic>Ccl21a</italic> as upregulated DEGs in IL-14&#x03B1;TG vs. C57BL/6 mouse SMG (<xref ref-type="fig" rid="F8">Figure&#x00A0;8E</xref>) and in human SjD vs. HV MSG (<xref ref-type="fig" rid="F8">Figure&#x00A0;8F</xref>). While <italic>Glycam1</italic> is a non-expressed pseudogene in humans, another HEV marker involved in lymphocyte migration, <italic>Fut7</italic> (fucosyltransferase 7) (<xref ref-type="bibr" rid="B54">54</xref>), was also significantly upregulated in SjD MSG (<xref ref-type="fig" rid="F8">Figure&#x00A0;8F</xref>).</p>
<fig id="F8" position="float"><label>Figure 8</label>
<caption><p>Expression, spatial localization and cell cluster distribution of germinal center and high endothelial venule gene markers in IL-14&#x03B1;TG and C57BL/6 mouse salivary glands. Color-coded expression [Log2(counts/capture area)] and cell cluster distribution violin plots of <bold>(A)</bold> <italic>Ltb</italic> (lymphotoxin-&#x03B2;, GC gene marker), <bold>(B)</bold> <italic>Cxcl13</italic> (C-X-C motif chemokine ligand 13, GC gene marker), <bold>(C)</bold> <italic>Glycam1</italic> (glycosylation dependent cell adhesion molecule 1, HEV gene marker) and <bold>(D)</bold> <italic>Ccl21</italic> (C-C motif chemokine ligand 21, HEV gene marker) in 12-month-old IL-14&#x03B1;TG and C57BL/6 mouse SMG and SLG; scale bar&#x2009;&#x003D;&#x2009;1&#x2005;mm. Volcano plots denoting GC and HEV DEG markers identified by RNAseq analysis of <bold>(D)</bold> 12-month-old IL-14&#x03B1;TG vs. C57BL/6 mouse SMG and <bold>(E)</bold> SjD patient vs. healthy volunteer MSG.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g008.tif"><alt-text content-type="machine-generated">Gene expression analysis in salivary gland tissues comparing IL-14&#x03B1;TG and C57BL/6 mice. Panels A-D show violin plots and tissue images for gene expression levels of Ltb, Cxcl13, Glycam1, and Ccl21 in different cell types. Panels E-F display volcano plots of differential expression between the groups, highlighting significant genes.</alt-text>
</graphic>
</fig>
<p>The most significantly upregulated and downregulated DEGs identified by RNAseq of 12-month-old IL-14&#x03B1;TG mouse SMG were the microtubule-associated protein gene <italic>Mid1</italic> and the mitogen-activated protein kinase gene <italic>Mapk9</italic>, respectively (<xref ref-type="fig" rid="F9">Figure&#x00A0;9</xref>). Both <italic>Mid1</italic> and <italic>Mapk9</italic> were also identified as DEGs in IL-14&#x03B1;TG mouse SMG at the 6-month timepoint (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>) and <italic>Mid1</italic> was identified as a unique SMG DEG that was differentially expressed with age in IL-14&#x03B1;TG, but not in C57BL/6 mouse SMG. Spatial transcriptomic analysis supported RNAseq findings, with broad <italic>Mid1</italic> expression observed in all cell clusters and enriched in activated B and T cell, SMG duct cell-enriched and sublingual gland cell clusters in the IL-14&#x03B1;TG mouse, whereas <italic>Mid1</italic> expression in C57BL/6 mouse SMG and SLG was sparse in all cell clusters (<xref ref-type="fig" rid="F9">Figure&#x00A0;9A</xref>). <italic>Mapk9</italic> expression was abundant in C57BL/6 mouse SMG and SLG and localized to all cell clusters, whereas <italic>Mapk9</italic> localization in IL-14&#x03B1;TG salivary glands was noted in all clusters, but was most abundant in neural cell-enriched and sublingual gland cell clusters (<xref ref-type="fig" rid="F9">Figure&#x00A0;9B</xref>). Neither <italic>Mid1</italic> nor <italic>Mapk9</italic> were identified as a DEG in human SjD MSG (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>).</p>
<fig id="F9" position="float"><label>Figure 9</label>
<caption><p><italic>Mid1</italic> and <italic>Mapk9</italic> expression, spatial localization and cell cluster distribution in IL-14&#x03B1;TG and C57BL/6 mouse salivary glands. Color-coded expression [Log2(counts/capture area)] and cell cluster distribution violin plots of <bold>(A)</bold> <italic>Mid1</italic> (midline 1; TRIM18) and <bold>(B)</bold> <italic>Mapk9</italic> (mitogen-activated protein kinase 9; c-Jun N-terminal kinase 2, JNK2) in 12-month-old IL-14&#x03B1;TG and C57BL/6 mouse SMG and SLG; scale bar&#x2009;&#x003D;&#x2009;1&#x2005;mm.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fdmed-06-1612522-g009.tif"><alt-text content-type="machine-generated">Histological images display IL-14&#x03B1;TG and C57BL/6 salivary gland tissues, annotated with dots indicating expression levels for Mid1 and Mapk9 genes. Colored bars beside each tissue sample indicate log2 expression levels. Adjacent violin plots show expression distribution across different cell types, such as SMG acinar and neural cells, highlighting variances between the two genotypes.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion"><title>Discussion</title>
<p>One key aspect of chronic human diseases is the lag time between disease onset and clinical diagnosis. While Sj&#x00F6;gren&#x0027;s disease is typically diagnosed in the 4th or 5th decade of life, many patients experience disease symptoms for years prior to diagnosis. As a result, clinical research samples are skewed towards advanced stages of disease, making it difficult to parse molecular mechanisms that contribute to early disease initiation. Therefore, identifying early drivers of disease is critical for enabling earlier diagnosis and intervention. Because the IL-14&#x03B1;TG mouse model has a well-defined temporal progression of SjD-like disease pathology, we can utilize both pre-symptomatic and post-symptomatic animals to compare molecular mechanisms of SjD and how they may be targeted therapeutically. Utilizing transcriptomic analyses to identify signaling pathways that are up or down regulated during disease progression could identify novel druggable targets or early diagnostic biomarkers that can be experimentally investigated in IL-14&#x03B1;TG mice at early or late stages of disease and then validated using human samples.</p>
<p>We investigated transcriptomic and histological changes in IL-14&#x03B1;TG and age-matched control C57BL/6 mouse SMG at 6 and 12 months of age, corresponding to time points preceding and subsequent to the development of sialadenitis in IL-14&#x03B1;TG mice (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>). The selection of comparative time points is of great importance in SjD-like mouse models due to the wide temporal range in disease development. In some SjD mouse models such as the NOD.B10-H2<sup>b</sup> and C57BL/6.NOD-<italic>Aec1Aec2</italic> mice, salivary gland dysfunction and sialadenitis can be detected as early as 12 weeks of age (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>), whereas SjD-like pathologies appear at 12&#x2013;14 months of age in BAFF/BLyS transgenic mice (<xref ref-type="bibr" rid="B57">57</xref>). In IL-14&#x03B1;TG mice, hypergammaglobulinemia can be detected in blood serum as early as 12 weeks of age, but salivary gland dysfunction (<italic>i.e.</italic>, loss of saliva secretion) is not measurable until 6 months of age and precedes the development of salivary and lacrimal gland inflammation that occurs at 9&#x2013;12 months of age (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B58">58</xref>). IL-14&#x03B1;TG mice were generated on a C57BL/6 background and previous studies have demonstrated that aged C57BL/6 mice also develop salivary and lacrimal gland inflammation by 12&#x2013;24 months of age (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B45">45</xref>). Indeed, our RNAseq comparison of 12-month-old vs. 6-month-old C57BL/6 mouse SMG showed significant enrichment of inflammatory pathways and biological processes that occur during aging (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). However, even after eliminating age as a variable by comparing age-matched 12-month-old IL-14&#x03B1;TG vs. C57BL/6 mouse SMG, we still observed significant enrichment of DEGs involved in inflammatory pathways and biological processes and our immunofluorescence and flow cytometry analyses further confirm the enhanced salivary gland inflammation in IL-14&#x03B1;TG mice compared to control (<xref ref-type="fig" rid="F1">Figures&#x00A0;1</xref>&#x2013;<xref ref-type="fig" rid="F3">3</xref>). We further controlled for age-associated inflammatory changes in C57BL/6 mice in our SMG RNAseq data by identifying and removing genes that were differentially expressed with age in both IL-14&#x03B1;TG and C57BL/6 genotypes to generate a list of DEGs that were unique to the IL-14&#x03B1;TG mouse SMG (<xref ref-type="fig" rid="F4">Figure&#x00A0;4</xref>). Again, gene ontology analysis identified significant enrichment of inflammatory and immune pathways that heavily overlapped with gene changes that occur in MSG biopsies of human SjD patients vs. healthy volunteers. Age-associated differential gene expression in salivary gland also likely occurs in human SjD patients and, considering that the disease is typically diagnosed between 40 and 55 years of age (<xref ref-type="bibr" rid="B4">4</xref>), age-associated gene expression should be considered as a confounding variable in future SjD studies and clinical trials. In the SjD vs. healthy volunteer MSG RNAseq dataset accessed through dbGAP (accession phs001842.v1.p1) and analyzed here, the median age of SjD patients at the time of biopsy was 52 while the median age of healthy volunteers was 29 (<xref ref-type="bibr" rid="B20">20</xref>).</p>
<p>The role of B cells in SjD pathogenesis has long been a focus of clinical investigation and B cell targeting therapies remain one of the few therapeutic options for severe or refractory SjD patients after failure of traditional treatment regimens (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B59">59</xref>). Previous studies have demonstrated significantly increased levels of germinal center, plasma and marginal zone B cells in the spleen of IL-14&#x03B1;TG mice compared to littermate controls, as well as increased B1 cell levels in the peritoneal cavity (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B58">58</xref>). In contrast to conventional B2 cell subsets that carry out humoral immunity, B1 cells are innate-like B cells primarily found in the peritoneal and pleural cavities that predominate during neonatal development (<xref ref-type="bibr" rid="B60">60</xref>). B1 cells possess the ability for self-renewal, generate the majority of IgM and IgA and have been shown to produce anti-phosphatidylserine and anti-dsDNA antibodies in systemic lupus erythematosus (SLE) and autoimmune diabetes mouse models (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>). Our data with SMG-infiltrating immune cells demonstrate that B1 cells are a minor B cell population in both IL-14&#x03B1;TG and C57BL/6 mouse SMG (&#x223C;5&#x0025;) and no statistical difference was observed between genotypes with regards to total B1 cells, CD5<sup>&#x002B;</sup> B1a cells that produce broadly reactive IgM, or CD5<sup>&#x2212;</sup> B1b cells that produce a T cell-independent, long lasting memory type of IgM (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B60">60</xref>). Marginal zone B cells possess innate-like immune cell qualities similar to B1 cells, but also participate in conventional humoral immune responses (<xref ref-type="bibr" rid="B63">63</xref>). While typically located in the splenic marginal zone between the white pulp and blood circulation, MZ B cells have been identified in MSG biopsies of SjD patients and in lymph nodes of SLE patients (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>). Unlike B1 cells, MZ B cells have been shown to play a central role in the development of the IL-14&#x03B1;TG mouse phenotype, where ablation of MZ B cells in IL-14&#x03B1;TG mice prevented the development of sialadenitis and salivary dysfunction, whereas ablation of B1 cells had no effect on disease phenotype (<xref ref-type="bibr" rid="B58">58</xref>). Our data demonstrate an increased proportion of MZ B cells in IL-14&#x03B1;TG compared to C57BL/6 mouse SMG, in line with previous analyses of splenic B cells (<xref ref-type="bibr" rid="B16">16</xref>). We further demonstrate increased expression of the MZ B cell marker gene <italic>Mzb1</italic> in both IL-14&#x03B1;TG mouse SMG and human SjD MSG (<xref ref-type="fig" rid="F7">Figure&#x00A0;7</xref>). MZ B cells were also identified by co-expression of <italic>CD19</italic> and CD21/35 (<italic>Cr1</italic> and <italic>Cr2</italic>; complement receptor 1 and 2) using spatial transcriptomics (<xref ref-type="sec" rid="s11">Supplementary Figure 6</xref>) and RNAseq analysis identified <italic>Cr1</italic> and <italic>Cr2</italic> as upregulated DEGs in both IL-14&#x03B1;TG mouse SMG and human SjD MSG (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). Interestingly, these complement receptors serve as the cell surface receptor for Epstein&#x2013;Barr virus (EBV) that exhibits tropism for B cells and has been suggested as an initiating factor in SjD pathogenesis (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B66">66</xref>). While specific contributions of MZ B cells to salivary gland dysfunction have not been clinically demonstrated in SjD patients, most SjD-associated lymphomas are MZ B cell neoplasms that include the MALT lymphoma subset (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>).</p>
<p>For other conventional B2 cell subsets, flow cytometry data showed no difference in proportional levels of SMG-infiltrating germinal center, plasma, follicular or memory B cells between genotypes at 12 months of age (<xref ref-type="fig" rid="F2">Figure&#x00A0;2C-D</xref>). However, total CD45<sup>&#x002B;</sup> immune cells were significantly increased in IL-14&#x03B1;TG mouse SMG (<xref ref-type="fig" rid="F2">Figure 2A</xref>) and RNAseq analysis identified numerous immune cell gene markers that were significantly upregulated compared to C57BL/6 mouse SMG, despite there being no difference in the proportion to total immune cells between genotypes. Among all immune cell types analyzed, plasma cells were the most abundant in both genotypes and the plasma cell gene marker <italic>Jchain</italic> was a significantly upregulated DEG in IL-14&#x03B1;TG vs. C57BL/6 mouse SMG (<xref ref-type="fig" rid="F7">Figure&#x00A0;7</xref>). These terminally differentiated antibody secreting B cells arising from either B1 or conventional B2 cell compartments mediate humoral immune responses under homeostatic conditions; however, plasma cells may also contribute to chronic autoinflammatory responses in SLE and SjD through autoantibody production (<xref ref-type="bibr" rid="B69">69</xref>). Plasma cells are typically resistant to B cell depletion therapies as they are non-dividing cells that lack CD20 expression, which may explain the low efficacy of B cell depletion therapies in SjD patients (<xref ref-type="bibr" rid="B69">69</xref>). When sorted by fold-change (log2FC), immunoglobulin genes represent 19 of the top 20 upregulated DEGs in the 12-month-old IL-14&#x03B1;TG mouse SMG (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>), further highlighting the significant increase in antibody production that occurs in this SjD mouse model. Although flow cytometry indicated a lower proportion of CD8<sup>&#x002B;</sup> T cells in IL-14&#x03B1;TG vs. C57BL/6 mouse SMG (<xref ref-type="fig" rid="F2">Figure 2F</xref>), RNAseq analysis identified the CD8 T cell gene marker <italic>CD8a</italic> as a significantly upregulated DEG in IL-14&#x03B1;TG mouse salivary gland and spatial transcriptomic analysis showed abundant <italic>CD8a</italic> expression in the activated B and T cell cluster (<xref ref-type="fig" rid="F7">Figure&#x00A0;7</xref>).</p>
<p>Similarly, the proportion of SMG-infiltrating GL7<sup>&#x002B;</sup> GC B cells was not significantly different between genotypes (<xref ref-type="fig" rid="F2">Figure 2C</xref>); however, the GC markers <italic>Ltb</italic> and <italic>Cxcl13</italic> were upregulated DEGs in 12-month-old IL-14&#x03B1;TG vs. C57BL/6 mouse SMG and highly expressed in the activated B and T cell and B cell-enriched clusters of IL-14&#x03B1;TG SMG (<xref ref-type="fig" rid="F8">Figure&#x00A0;8</xref>). Germinal centers are typically found in secondary lymphoid tissue such as spleen and lymph nodes where they develop in response to antigen recognition by B cells that migrate through a specialized network of follicular dendritic cells and T cells to undergo affinity-dependent selection and clonal expansion (<xref ref-type="bibr" rid="B39">39</xref>). GC formation in non-lymphoid tissues also occurs during autoimmune disease pathogenesis and spontaneous ectopic GC formation is a hallmark of many autoimmune disease mouse models (<xref ref-type="bibr" rid="B70">70</xref>). Spontaneous GC-like lymphoid structures and GL7<sup>&#x002B;</sup> GC B cells have also been described in 13-14-month-old C57BL/6 mouse SMG (<xref ref-type="bibr" rid="B45">45</xref>) and our data further support the concept of spontaneous sialadenitis, GC formation and subsequent loss of salivary gland function in aged C57BL/6 mouse exocrine tissues. In the IL-14&#x03B1;TG mouse model, these age-associated immune responses are compounded such that even after controlling for age as a variable, we still observe significantly increased levels of GC gene markers <italic>Ltb</italic> and <italic>Cxcl13</italic>. In human SjD MSG, gene ontology analysis of DEGs identified GC formation as an enriched biological process, with the upregulation of GC-associated genes Tnfsf13b (BAFF/BlyS), <italic>Ada</italic>, <italic>Klhl6</italic>, and <italic>Unc13d</italic> (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). While previous studies suggest that only &#x223C;25&#x0025; of SjD patient MSG biopsies contain GC-like structures at the time of diagnosis, their presence may have prognostic value and is associated with an &#x223C;8-fold increase in the risk of developing non-Hodgkin lymphoma (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B71">71</xref>).</p>
<p>While our flow cytometric and transcriptomic analyses focused on lymphocytes and adaptive immune responses, innate immune processes and interferon (IFN) signaling also contribute to salivary gland dysfunction in SjD (<xref ref-type="bibr" rid="B72">72</xref>). Elevated IFN-inducible gene expression has been observed in SjD patient salivary glands and peripheral blood mononuclear cells (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>) and single nucleotide polymorphisms associated with SjD development have been identified in numerous IFN-inducible genes involved in innate immunity, including interferon regulatory factor 5 (<italic>Irf5</italic>), signal transducer and activator of transcription 4 (<italic>Stat4</italic>) and human leukocyte antigen (HLA) genes (<xref ref-type="bibr" rid="B75">75</xref>). Bulk RNAseq analysis identified numerous differentially expressed IFN-inducible genes, including <italic>Irf5</italic>, <italic>Irf8</italic>, <italic>Ifit3b</italic> and <italic>Ifi47</italic> in 12-month-old IL-14&#x03B1;TG vs. C57BL/6 SMGs and <italic>Irf8</italic>, <italic>Irf1</italic>, <italic>Ifit3</italic> and <italic>Ifi44</italic> in SjD vs. HV MSGs (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). Furthermore, the toll-like receptor (TLR) genes <italic>Tlr7</italic>, <italic>Tlr9</italic> and <italic>Tlr10</italic> were also identified as DEGs in both human and mouse datasets, suggesting that innate immune responses contribute to SjD pathogenesis (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>).</p>
<p>In addition to immune cell and GC gene markers, RNAseq analysis identified the high endothelial venule gene marker <italic>Glycam1</italic> as one of the top DEGs in 12-month-old IL-14&#x03B1;TG compared to C57BL/6 mouse SMG and spatial transcriptomic analysis revealed abundant expression of <italic>Glycam1</italic> and the HEV-associated chemokine <italic>Ccl21</italic> in the activated B and T cell and B cell-enriched clusters of IL-14&#x03B1;TG mouse SMG (<xref ref-type="fig" rid="F8">Figure&#x00A0;8</xref>). HEVs are specialized blood vessel structures that promote lymphocyte trafficking from the bloodstream into surrounding tissue through expression of various cell adhesion molecules, selectins, chemokines and enzymes (<xref ref-type="bibr" rid="B53">53</xref>). Like GCs, HEVs are typically found in secondary lymphoid tissues where they function in homeostatic immunosurveillance, but have also been identified in chronically inflamed non-lymphoid tissues in autoimmune diseases, including synovium in rheumatoid arthritis and salivary glands in SjD patients (<xref ref-type="bibr" rid="B76">76</xref>). <italic>Glycam1</italic><sup>&#x002B;</sup> HEVs have been identified in inflamed salivary and lacrimal glands of NOD mice, where lymphotoxin-&#x03B2; receptor signaling was essential for their development (<xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B78">78</xref>), as well as in 24-month-old C57BL/6 mouse lacrimal glands (<xref ref-type="bibr" rid="B38">38</xref>), further highlighting the overlap of age-associated inflammatory processes and autoimmune-mediated pathologies. While <italic>Glycam1</italic> is a pseudogene in humans, our RNAseq analysis of SjD patient MSGs identified two other HEV gene markers, <italic>Fut7</italic> and <italic>Ccl21</italic> (<xref ref-type="bibr" rid="B54">54</xref>), as upregulated DEGs compared to healthy volunteer MSGs (<xref ref-type="fig" rid="F8">Figure&#x00A0;8</xref>). Because HEV formation is preceded by tissue lymphocyte accumulation and is often associated with ectopic GCs (<xref ref-type="bibr" rid="B76">76</xref>), HEVs aren&#x0027;t likely to be a causative agent for chronic inflammation, but may represent a therapeutic target to reduce lymphocyte trafficking into inflamed tissue.</p>
<p>RNAseq analysis identified <italic>Mid1</italic> and <italic>Mapk9</italic> as the top upregulated and downregulated DEGs, respectively, in 12-month-old IL-14&#x03B1;TG vs. C57BL/6 mouse SMG (<xref ref-type="fig" rid="F3">Figure 3C</xref>) and <italic>Mid1</italic> and <italic>Mapk9</italic> were 2 of 9 total genes that were differentially expressed in IL-14&#x03B1;TG mouse SMG at both the 6- and 12-month time points (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). <italic>Mid1</italic> encodes a member of the interferon-inducible tripartite motif family of proteins, (TRIM18; midline 1), and mutations in this cytoplasmic microtubule-associated protein are causally implicated in X-linked Opitz G/BBB syndrome characterized by abnormalities such as cleft lip, heart defects and agenesis of the corpus callosum (<xref ref-type="bibr" rid="B79">79</xref>). Mid1 exhibits E3 ubiquitin ligase activity targeting the Alpha4 (&#x03B1;4) protein (<xref ref-type="bibr" rid="B80">80</xref>), a microtubule-associated protein regulatory subunit originally identified as an Ig receptor binding protein that contributes to B cell receptor signaling (<xref ref-type="bibr" rid="B81">81</xref>). By regulating ubiquitin-mediated degradation of &#x03B1;4, Mid1 modulates the assembly of the mammalian target of rapamycin complex 1 (mTORC1) that has been investigated for treatment of lacrimal and salivary gland pathologies in SjD patients (<xref ref-type="bibr" rid="B82">82</xref>&#x2013;<xref ref-type="bibr" rid="B84">84</xref>). <italic>Mapk9</italic> encodes c-Jun N-terminal kinase 2 (JNK2), a primary regulator of the c-Jun component of the activator protein-1 (AP-1) family of transcription factors, which has been shown to contribute to peripheral T cell activation in response to extracellular cytokines and proinflammatory activators (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>). JNK2 knockout confers protection against insulitis and diabetes development in NOD mice and pharmacological JNK2 inhibition increased tear production in the MRL/lpr mouse model of SjD (<xref ref-type="bibr" rid="B87">87</xref>, <xref ref-type="bibr" rid="B88">88</xref>). In the NOD.B10-H2<sup>b</sup> SjD mouse model, bulk RNAseq analysis of SMGs identified <italic>Mapk9</italic> as an upregulated DEG compared to C57BL/10 control mice at 7 months of age and scRNAseq demonstrated <italic>Mapk9</italic> enrichment in the excretory duct and NK cell compartments (<xref ref-type="bibr" rid="B27">27</xref>). The discrepancy between downregulation and upregulation of <italic>Mapk9</italic> expression in IL-14&#x03B1;TG and NOD.B10-H2<sup>b</sup> mice, respectively, likely reflects the heterogeneity of SjD mouse models and the relative contributions of B and T lymphocytes to SMG pathologies. Neither <italic>Mid1</italic> nor <italic>Mapk9</italic> were identified as DEGs in SjD MSG biopsies; however, alternative gene products that carry out similar cellular functions were identified, including the gene encoding the microtubule-associated protein TRIM46 that functions in neuronal axon specification and polarity (<xref ref-type="bibr" rid="B89">89</xref>) and <italic>Mapk12</italic> encoding p38&#x03B3; that negatively regulates c-Jun expression and subsequent AP-1 transcription factor activity (<xref ref-type="bibr" rid="B90">90</xref>).</p>
<p>In summary, we assessed chronic autoimmune sialadenitis in IL-14&#x03B1;TG mouse SMG using immunofluorescence, flow cytometry, bulk RNAseq and spatial transcriptomic analyses and compared the results to previous findings in salivary glands of SjD mouse models and minor salivary gland biopsies from human SjD patients. We highlighted the overlapping inflammatory signatures of DEGs in SMGs of age-matched IL-14&#x03B1;TG vs. control C57BL/6 mice and MSGs of SjD patients vs. healthy volunteers, while also confirming previous observations of age-associated inflammatory changes in mouse salivary and lacrimal glands. One of the limitations of this study is the disease stage of the tissue samples that were analyzed. In mouse tissues, the C57BL/6 control group exhibited significant age-associated inflammatory changes that were difficult to parse from autoimmune-mediated inflammatory changes. Further examination of the SjD-like phenotype of IL-14&#x03B1;TG mice from 3 to 9 months of age, corresponding to asymptomatic and mild symptomatic time points when tissues are less inflamed, may offer further mechanistic insight into disease-initiating factors that can be targeted therapeutically. In the human RNAseq dataset, the median age difference of SjD patients and healthy volunteers at the time of MSG biopsy represents an uncontrolled variable that should be considered when scrutinizing our findings in humans. Limitations of the arrayed poly(dT)-based spatial transcriptomic analysis include low resolution resulting from the 55&#x2005;&#x00B5;m diameter capture areas and the high dependence on the tissue sections chosen for comparison. The large capture areas encompassing multiple cell types and the resulting pool of barcoded mRNA from these cells make cell clustering challenging. The SMG and SLG tissue sections chosen for comparison can further impact experimental effectiveness and reproducibility due to the high spatial heterogeneity of salivary glands. For example, the 10&#x2005;&#x00B5;m IL-14&#x03B1;TG mouse salivary tissue section analyzed here by spatial transcriptomics included a large portion of the main excretory duct and facial nerve, whereas the C57BL/6 tissue section did not contain either. Similarly, clusters of activated B and T cells were not identified in the C57BL/6 mouse SMG and it is unclear whether these cells were not present in the intact salivary gland or just absent in the chosen tissue section. Nonetheless, the complementary use of whole tissue RNAseq analysis offered clarity in identifying upregulated gene markers of activated B and T cells (<italic>i.e.</italic>, <italic>Ltb</italic> and <italic>Cxcl13</italic>) in the IL-14&#x03B1;TG mouse SMG, giving greater confidence that these cell types are more abundant in this SjD-like mouse compared to control C57BL/6 mouse SMG. Despite technical limitations, the use of unbiased bulk and spatial transcriptomic profiling to refine interpretations of existing data offers a powerful approach to support hypothesis-driven research.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability"><title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>.</p>
</sec>
<sec id="s6" sec-type="ethics-statement"><title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. The animal study was approved by the University of Missouri Animal Care and Use Committee. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec id="s7" sec-type="author-contributions"><title>Author contributions</title>
<p>LW: Conceptualization, Investigation, Visualization, Data curation, Writing &#x2013; review &#x0026; editing, Formal analysis, Writing &#x2013; original draft, Methodology. KJ: Conceptualization, Writing &#x2013; review &#x0026; editing, Methodology, Formal analysis, Investigation, Writing &#x2013; original draft, Data curation, Software, Visualization. KM: Investigation, Writing &#x2013; review &#x0026; editing, Formal analysis, Methodology, Writing &#x2013; original draft. AK: Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft. GW: Funding acquisition, Writing &#x2013; review &#x0026; editing, Resources, Writing &#x2013; original draft, Conceptualization, Supervision.</p>
</sec>
<sec id="s8" sec-type="funding-information"><title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. Research reported in this publication was supported by the National Institute of Dental &#x0026; Craniofacial Research of the National Institutes of Health under Award Numbers R01DE029833 and R01DE029833-S1. KM was supported by the Wayne L. Ryan fellowship from The Ryan Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or The Ryan Foundation.</p>
</sec>
<ack><title>Acknowledgments</title>
<p>We thankfully acknowledge the Salivary Disorders Clinic at the National Institute of Dental and Craniofacial Research, National Institutes of Health for providing the human RNA sequencing data accessed through dbGAP accession phs001842.v1.p1.</p>
</ack>
<sec id="s9" sec-type="COI-statement"><title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="ai-statement"><title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s12" sec-type="disclaimer"><title>Publisher&#x0027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material"><title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fdmed.2025.1612522/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fdmed.2025.1612522/full&#x0023;supplementary-material</ext-link></p>
<supplementary-material id="SD1" content-type="local-data">
<media mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="Datasheet1.docx"/></supplementary-material>
<supplementary-material id="SD2" content-type="local-data">
<media mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="Table1.xlsx"/></supplementary-material>
<supplementary-material id="SD3" content-type="local-data">
<media mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="Table2.xlsx"/></supplementary-material>
</sec>
<ref-list><title>References</title>
<ref id="B1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shiboski</surname><given-names>CH</given-names></name><name><surname>Shiboski</surname><given-names>SC</given-names></name><name><surname>Seror</surname><given-names>R</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><name><surname>Labetoulle</surname><given-names>M</given-names></name><name><surname>Lietman</surname><given-names>TM</given-names></name><etal/></person-group> <article-title>2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren&#x2019;s syndrome: a consensus and data-driven methodology involving three international patient cohorts</article-title>. <source>Arthritis Rheumatol</source>. (<year>2017</year>) <volume>69</volume>(<issue>1</issue>):<fpage>35</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1002/art.39859</pub-id><pub-id pub-id-type="pmid">27785888</pub-id></citation></ref>
<ref id="B2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Negrini</surname><given-names>S</given-names></name><name><surname>Emmi</surname><given-names>G</given-names></name><name><surname>Greco</surname><given-names>M</given-names></name><name><surname>Borro</surname><given-names>M</given-names></name><name><surname>Sardanelli</surname><given-names>F</given-names></name><name><surname>Murdaca</surname><given-names>G</given-names></name><etal/></person-group> <article-title>Sjogren&#x2019;s syndrome: a systemic autoimmune disease</article-title>. <source>Clin Exp Med</source>. (<year>2022</year>) <volume>22</volume>(<issue>1</issue>):<fpage>9</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1007/s10238-021-00728-6</pub-id><pub-id pub-id-type="pmid">34100160</pub-id></citation></ref>
<ref id="B3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nocturne</surname><given-names>G</given-names></name><name><surname>Virone</surname><given-names>A</given-names></name><name><surname>Ng</surname><given-names>WF</given-names></name><name><surname>Le Guern</surname><given-names>V</given-names></name><name><surname>Hachulla</surname><given-names>E</given-names></name><name><surname>Cornec</surname><given-names>D</given-names></name><etal/></person-group> <article-title>Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren&#x2019;s syndrome</article-title>. <source>Arthritis Rheumatol</source>. (<year>2016</year>) <volume>68</volume>(<issue>4</issue>):<fpage>977</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1002/art.39518</pub-id><pub-id pub-id-type="pmid">26606524</pub-id></citation></ref>
<ref id="B4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vivino</surname><given-names>FB</given-names></name></person-group>. <article-title>Sjogren&#x2019;s syndrome: clinical aspects</article-title>. <source>Clin Immunol</source>. (<year>2017</year>) <volume>182</volume>:<fpage>48</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2017.04.005</pub-id><pub-id pub-id-type="pmid">28428095</pub-id></citation></ref>
<ref id="B5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Brito-Zeron</surname><given-names>P</given-names></name><name><surname>Bombardieri</surname><given-names>S</given-names></name><name><surname>Bootsma</surname><given-names>H</given-names></name><name><surname>De Vita</surname><given-names>S</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Eular recommendations for the management of Sjogren&#x2019;s syndrome with topical and systemic therapies</article-title>. <source>Ann Rheum Dis</source>. (<year>2020</year>) <volume>79</volume>(<issue>1</issue>):<fpage>3</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2019-216114</pub-id><pub-id pub-id-type="pmid">31672775</pub-id></citation></ref>
<ref id="B6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saraux</surname><given-names>A</given-names></name><name><surname>Pers</surname><given-names>JO</given-names></name><name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name></person-group>. <article-title>Treatment of primary Sj&#x00F6;gren syndrome</article-title>. <source>Nat Rev Rheumatol</source>. (<year>2016</year>) <volume>12</volume>(<issue>8</issue>):<fpage>456</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2016.100</pub-id><pub-id pub-id-type="pmid">27411907</pub-id></citation></ref>
<ref id="B7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mielle</surname><given-names>J</given-names></name><name><surname>Tison</surname><given-names>A</given-names></name><name><surname>Cornec</surname><given-names>D</given-names></name><name><surname>Le Pottier</surname><given-names>L</given-names></name><name><surname>Daien</surname><given-names>C</given-names></name><name><surname>Pers</surname><given-names>JO</given-names></name></person-group>. <article-title>B cells in Sjogren&#x2019;s syndrome: from pathophysiology to therapeutic target</article-title>. <source>Rheumatology (Oxford)</source>. (<year>2021</year>) <volume>60</volume>(<issue>6</issue>):<fpage>2545</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/key332</pub-id><pub-id pub-id-type="pmid">30770916</pub-id></citation></ref>
<ref id="B8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sene</surname><given-names>D</given-names></name><name><surname>Ismael</surname><given-names>S</given-names></name><name><surname>Forien</surname><given-names>M</given-names></name><name><surname>Charlotte</surname><given-names>F</given-names></name><name><surname>Kaci</surname><given-names>R</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><etal/></person-group> <article-title>Ectopic germinal center-like structures in Minor salivary gland biopsy tissue predict lymphoma occurrence in patients with primary Sjogren&#x2019;s syndrome</article-title>. <source>Arthritis Rheumatol</source>. (<year>2018</year>) <volume>70</volume>(<issue>9</issue>):<fpage>1481</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/art.40528</pub-id><pub-id pub-id-type="pmid">29669392</pub-id></citation></ref>
<ref id="B9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowman</surname><given-names>SJ</given-names></name><name><surname>Everett</surname><given-names>CC</given-names></name><name><surname>O&#x0027;Dwyer</surname><given-names>JL</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Pitzalis</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>WF</given-names></name><etal/></person-group> <article-title>Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren&#x2019;s syndrome</article-title>. <source>Arthritis Rheumatol</source>. (<year>2017</year>) <volume>69</volume>(<issue>7</issue>):<fpage>1440</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1002/art.40093</pub-id><pub-id pub-id-type="pmid">28296257</pub-id></citation></ref>
<ref id="B10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>JM</given-names></name><name><surname>Meiners</surname><given-names>PM</given-names></name><name><surname>Vissink</surname><given-names>A</given-names></name><name><surname>Spijkervet</surname><given-names>FK</given-names></name><name><surname>Abdulahad</surname><given-names>W</given-names></name><name><surname>Kamminga</surname><given-names>N</given-names></name><etal/></person-group> <article-title>Effectiveness of rituximab treatment in primary Sjogren&#x2019;s syndrome: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Arthritis Rheum</source>. (<year>2010</year>) <volume>62</volume>(<issue>4</issue>):<fpage>960</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/art.27314</pub-id><pub-id pub-id-type="pmid">20131246</pub-id></citation></ref>
<ref id="B11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name><name><surname>Jousse-Joulin</surname><given-names>S</given-names></name><name><surname>Berthelot</surname><given-names>JM</given-names></name><name><surname>Perdriger</surname><given-names>A</given-names></name><name><surname>Puechal</surname><given-names>X</given-names></name><etal/></person-group> <article-title>Treatment of primary Sjogren syndrome with rituximab: a randomized trial</article-title>. <source>Ann Intern Med</source>. (<year>2014</year>) <volume>160</volume>(<issue>4</issue>):<fpage>233</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.7326/M13-1085</pub-id><pub-id pub-id-type="pmid">24727841</pub-id></citation></ref>
<ref id="B12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gottenberg</surname><given-names>JE</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name><name><surname>Bootsma</surname><given-names>H</given-names></name><name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name><name><surname>Bowman</surname><given-names>SJ</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name><etal/></person-group> <article-title>Efficacy of epratuzumab, an anti-Cd22 monoclonal igg antibody, in systemic lupus erythematosus patients with associated Sjogren&#x2019;s syndrome: <italic>post hoc</italic> analyses from the embody trials</article-title>. <source>Arthritis Rheumatol</source>. (<year>2018</year>) <volume>70</volume>(<issue>5</issue>):<fpage>763</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1002/art.40425</pub-id><pub-id pub-id-type="pmid">29381843</pub-id></citation></ref>
<ref id="B13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mariette</surname><given-names>X</given-names></name><name><surname>Barone</surname><given-names>F</given-names></name><name><surname>Baldini</surname><given-names>C</given-names></name><name><surname>Bootsma</surname><given-names>H</given-names></name><name><surname>Clark</surname><given-names>KL</given-names></name><name><surname>De Vita</surname><given-names>S</given-names></name><etal/></person-group> <article-title>A randomized, phase ii study of sequential belimumab and rituximab in primary Sjogren&#x2019;s syndrome</article-title>. <source>JCI Insight</source>. (<year>2022</year>) <volume>7</volume>(<issue>23</issue>):<fpage>e163030</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.163030</pub-id><pub-id pub-id-type="pmid">36477362</pub-id></citation></ref>
<ref id="B14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorner</surname><given-names>T</given-names></name><name><surname>Kaul</surname><given-names>M</given-names></name><name><surname>Szanto</surname><given-names>A</given-names></name><name><surname>Tseng</surname><given-names>JC</given-names></name><name><surname>Papas</surname><given-names>AS</given-names></name><name><surname>Pylvaenaeinen</surname><given-names>I</given-names></name><etal/></person-group> <article-title>Efficacy and safety of remibrutinib, a selective potent oral btk inhibitor, in Sjogren&#x2019;s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial</article-title>. <source>Ann Rheum Dis</source>. (<year>2024</year>) <volume>83</volume>(<issue>3</issue>):<fpage>360</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1136/ard-2023-224691</pub-id><pub-id pub-id-type="pmid">37932009</pub-id></citation></ref>
<ref id="B15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaklamanos</surname><given-names>A</given-names></name><name><surname>Goules</surname><given-names>AV</given-names></name><name><surname>Tzioufas</surname><given-names>AG</given-names></name></person-group>. <article-title>Experimental models of Sjogren&#x2019;s syndrome: differences and similarities with human disease</article-title>. <source>Clin Exp Rheumatol</source>. (<year>2022</year>) <volume>40</volume>(<issue>12</issue>):<fpage>2398</fpage>&#x2013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.55563/clinexprheumatol/d4cx78</pub-id><pub-id pub-id-type="pmid">36305363</pub-id></citation></ref>
<ref id="B16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Brooks</surname><given-names>S</given-names></name><name><surname>Ford</surname><given-names>RJ</given-names></name><name><surname>Lin-Lee</surname><given-names>YC</given-names></name><etal/></person-group> <article-title>Development of autoimmunity in il-14alpha-transgenic mice</article-title>. <source>J Immunol</source>. (<year>2006</year>) <volume>177</volume>(<issue>8</issue>):<fpage>5676</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.177.8.5676</pub-id><pub-id pub-id-type="pmid">17015757</pub-id></citation></ref>
<ref id="B17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Suresh</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Pankewycz</surname><given-names>O</given-names></name><etal/></person-group> <article-title>Il-14 alpha, the nexus for primary Sj&#x00F6;gren&#x2019;s disease in mice and humans</article-title>. <source>Clin Immunol</source>. (<year>2009</year>) <volume>130</volume>(<issue>3</issue>):<fpage>304</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2008.10.006</pub-id><pub-id pub-id-type="pmid">19038581</pub-id></citation></ref>
<ref id="B18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xuan</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Malyavantham</surname><given-names>K</given-names></name><name><surname>Pankewycz</surname><given-names>O</given-names></name><name><surname>Ambrus</surname><given-names>JL</given-names><suffix>Jr</suffix></name><name><surname>Suresh</surname><given-names>L</given-names></name></person-group>. <article-title>Temporal histological changes in lacrimal and Major salivary glands in mouse models of Sjogren&#x2019;s syndrome</article-title>. <source>BMC Oral Health</source>. (<year>2013</year>) <volume>13</volume>:<fpage>51</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6831-13-51</pub-id><pub-id pub-id-type="pmid">24093879</pub-id></citation></ref>
<ref id="B19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Suresh</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Xuan</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group> <article-title>A role for lymphotoxin in primary Sjogren&#x2019;s disease</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>185</volume>(<issue>10</issue>):<fpage>6355</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1001520</pub-id><pub-id pub-id-type="pmid">20952683</pub-id></citation></ref>
<ref id="B20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>SI</given-names></name><name><surname>Tandon</surname><given-names>M</given-names></name><name><surname>Teos</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Warner</surname><given-names>BM</given-names></name><name><surname>Alevizos</surname><given-names>I</given-names></name></person-group>. <article-title>Dual function of mir-1248 links interferon induction and calcium signaling defects in Sjogren&#x2019;s syndrome</article-title>. <source>EBioMedicine</source>. (<year>2019</year>) <volume>48</volume>:<fpage>526</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2019.09.010</pub-id><pub-id pub-id-type="pmid">31597594</pub-id></citation></ref>
<ref id="B21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oyelakin</surname><given-names>A</given-names></name><name><surname>Horeth</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>EC</given-names></name><name><surname>Min</surname><given-names>S</given-names></name><name><surname>Che</surname><given-names>M</given-names></name><name><surname>Marzullo</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Transcriptomic and network analysis of Minor salivary glands of patients with primary Sj&#x00F6;gren&#x2019;s syndrome</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>606268</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.606268</pub-id><pub-id pub-id-type="pmid">33488608</pub-id></citation></ref>
<ref id="B22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nayar</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>JD</given-names></name><name><surname>Asam</surname><given-names>S</given-names></name><name><surname>Fennell</surname><given-names>E</given-names></name><name><surname>Pugh</surname><given-names>M</given-names></name><name><surname>Colafrancesco</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Molecular and spatial analysis of tertiary lymphoid structures in Sjogren&#x2019;s syndrome</article-title>. <source>Nat Commun</source>. (<year>2025</year>) <volume>16</volume>(<issue>1</issue>):<fpage>5</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-024-54686-0</pub-id><pub-id pub-id-type="pmid">39747819</pub-id></citation></ref>
<ref id="B23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group> <article-title>Single-cell transcriptome profiling reveals immune and stromal cell heterogeneity in primary Sj&#x00F6;gren&#x2019;s syndrome</article-title>. <source>iScience</source>. (<year>2023</year>) <volume>26</volume>(<issue>10</issue>):<fpage>107943</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2023.107943</pub-id><pub-id pub-id-type="pmid">37810210</pub-id></citation></ref>
<ref id="B24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group>. <article-title>Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sj&#x00F6;gren&#x2019;s syndrome</article-title>. <source>J Transl Autoimmun</source>. (<year>2024</year>) <volume>9</volume>:<fpage>100248</fpage>. <pub-id pub-id-type="doi">10.1016/j.jtauto.2024.100248</pub-id><pub-id pub-id-type="pmid">39131726</pub-id></citation></ref>
<ref id="B25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>BR</given-names></name><name><surname>Aure</surname><given-names>MH</given-names></name><name><surname>Kelly</surname><given-names>MC</given-names></name></person-group>, <collab>Genomics and Computational Biology Core</collab>, <person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>MP</given-names></name><name><surname>Chibly</surname><given-names>AM</given-names></name></person-group>. <article-title>Generation of a single-cell rnaseq atlas of murine salivary gland development</article-title>. <source>iScience</source>. (<year>2020</year>) <volume>23</volume>(<issue>12</issue>):<fpage>101838</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2020.101838</pub-id><pub-id pub-id-type="pmid">33305192</pub-id></citation></ref>
<ref id="B26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mauduit</surname><given-names>O</given-names></name><name><surname>Delcroix</surname><given-names>V</given-names></name><name><surname>Umazume</surname><given-names>T</given-names></name><name><surname>de Paiva</surname><given-names>CS</given-names></name><name><surname>Dartt</surname><given-names>DA</given-names></name><name><surname>Makarenkova</surname><given-names>HP</given-names></name></person-group>. <article-title>Spatial transcriptomics of the lacrimal gland features macrophage activity and epithelium metabolism as key alterations during chronic inflammation</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<fpage>1011125</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.1011125</pub-id><pub-id pub-id-type="pmid">36341342</pub-id></citation></ref>
<ref id="B27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horeth</surname><given-names>E</given-names></name><name><surname>Oyelakin</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>EC</given-names></name><name><surname>Che</surname><given-names>M</given-names></name><name><surname>Bard</surname><given-names>J</given-names></name><name><surname>Min</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Transcriptomic and single-cell analysis reveals regulatory networks and cellular heterogeneity in mouse primary Sj&#x00F6;gren&#x2019;s syndrome salivary glands</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>729040</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.729040</pub-id><pub-id pub-id-type="pmid">34912329</pub-id></citation></ref>
<ref id="B28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>PL</given-names></name><name><surname>Salmen</surname><given-names>F</given-names></name><name><surname>Vickovic</surname><given-names>S</given-names></name><name><surname>Lundmark</surname><given-names>A</given-names></name><name><surname>Navarro</surname><given-names>JF</given-names></name><name><surname>Magnusson</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Visualization and analysis of gene expression in tissue sections by spatial transcriptomics</article-title>. <source>Science</source>. (<year>2016</year>) <volume>353</volume>(<issue>6294</issue>):<fpage>78</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaf2403</pub-id><pub-id pub-id-type="pmid">27365449</pub-id></citation></ref>
<ref id="B29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piwecka</surname><given-names>M</given-names></name><name><surname>Rajewsky</surname><given-names>N</given-names></name><name><surname>Rybak-Wolf</surname><given-names>A</given-names></name></person-group>. <article-title>Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease</article-title>. <source>Nat Rev Neurol</source>. (<year>2023</year>) <volume>19</volume>(<issue>6</issue>):<fpage>346</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-023-00809-y</pub-id><pub-id pub-id-type="pmid">37198436</pub-id></citation></ref>
<ref id="B30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huynh</surname><given-names>KLA</given-names></name><name><surname>Tyc</surname><given-names>KM</given-names></name><name><surname>Matuck</surname><given-names>BF</given-names></name><name><surname>Easter</surname><given-names>QT</given-names></name><name><surname>Pratapa</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>NV</given-names></name><etal/></person-group> <article-title>Deconvolution of cell types and states in spatial multiomics utilizing TACIT</article-title>. <source>Nat Commun</source>. (<year>2025</year>) <volume>16</volume>(<issue>1</issue>):<fpage>3747</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-025-58874-4</pub-id><pub-id pub-id-type="pmid">40258827</pub-id></citation></ref>
<ref id="B31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pranzatelli</surname><given-names>TJF</given-names></name><name><surname>Perez</surname><given-names>P</given-names></name><name><surname>Ku</surname><given-names>A</given-names></name><name><surname>Matuck</surname><given-names>B</given-names></name><name><surname>Huynh</surname><given-names>K</given-names></name><name><surname>Sakai</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Gzmk&#x002B;Cd8&#x002B; T cells target a specific acinar cell type in sjogren&#x2019;s disease</article-title>. <source>Res Sq</source>. (<year>2024</year>). <pub-id pub-id-type="doi">10.21203/rs.3.rs-3601404/v1</pub-id></citation></ref>
<ref id="B32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name></person-group>. <article-title>Ultrafast one-pass fastq data preprocessing, quality control, and deduplication using fastp</article-title>. <source>Imeta</source>. (<year>2023</year>) <volume>2</volume>(<issue>2</issue>):<fpage>e107</fpage>. <pub-id pub-id-type="doi">10.1002/imt2.107</pub-id><pub-id pub-id-type="pmid">38868435</pub-id></citation></ref>
<ref id="B33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Star: ultrafast universal RNA-Seq aligner</article-title>. <source>Bioinformatics</source>. (<year>2013</year>) <volume>29</volume>(<issue>1</issue>):<fpage>15</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></citation></ref>
<ref id="B34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group>. <article-title>Moderated estimation of fold change and dispersion for RNA-Seq data with Deseq2</article-title>. <source>Genome Biol</source>. (<year>2014</year>) <volume>15</volume>(<issue>12</issue>):<fpage>550</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></citation></ref>
<ref id="B35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goedhart</surname><given-names>J</given-names></name><name><surname>Luijsterburg</surname><given-names>MS</given-names></name></person-group>. <article-title>Volcanoser is a web app for creating, exploring, labeling and sharing volcano plots</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>(<issue>1</issue>):<fpage>20560</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-76603-3</pub-id><pub-id pub-id-type="pmid">33239692</pub-id></citation></ref>
<ref id="B36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Hao</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Baseler</surname><given-names>MW</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><etal/></person-group> <article-title>David: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)</article-title>. <source>Nucleic Acids Res</source>. (<year>2022</year>) <volume>50</volume>(<issue>W1</issue>):<fpage>W216</fpage>&#x2013;<lpage>W21</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac194</pub-id><pub-id pub-id-type="pmid">35325185</pub-id></citation></ref>
<ref id="B37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang da</surname><given-names>W</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group>. <article-title>Systematic and integrative analysis of large gene lists using David bioinformatics resources</article-title>. <source>Nat Protoc</source>. (<year>2009</year>) <volume>4</volume>(<issue>1</issue>):<fpage>44</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></citation></ref>
<ref id="B38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galletti</surname><given-names>JG</given-names></name><name><surname>Scholand</surname><given-names>KK</given-names></name><name><surname>Trujillo-Vargas</surname><given-names>CM</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Mauduit</surname><given-names>O</given-names></name><name><surname>Delcroix</surname><given-names>V</given-names></name><etal/></person-group> <article-title>Ectopic lymphoid structures in the aged lacrimal glands</article-title>. <source>Clin Immunol</source>. (<year>2023</year>) <volume>248</volume>:<fpage>109251</fpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2023.109251</pub-id><pub-id pub-id-type="pmid">36740002</pub-id></citation></ref>
<ref id="B39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Victora</surname><given-names>GD</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group>. <article-title>Germinal centers</article-title>. <source>Annu Rev Immunol</source>. (<year>2022</year>) <volume>40</volume>:<fpage>413</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-120419-022408</pub-id><pub-id pub-id-type="pmid">35113731</pub-id></citation></ref>
<ref id="B40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sumi</surname><given-names>M</given-names></name><name><surname>Izumi</surname><given-names>M</given-names></name><name><surname>Yonetsu</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group>. <article-title>Sublingual gland: MR features of normal and diseased states</article-title>. <source>AJR Am J Roentgenol</source>. (<year>1999</year>) <volume>172</volume>(<issue>3</issue>):<fpage>717</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.2214/ajr.172.3.10063867</pub-id><pub-id pub-id-type="pmid">10063867</pub-id></citation></ref>
<ref id="B41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>B</given-names></name><name><surname>Morel</surname><given-names>L</given-names></name></person-group>. <article-title>Role of B-1a cells in autoimmunity</article-title>. <source>Autoimmun Rev</source>. (<year>2006</year>) <volume>5</volume>(<issue>6</issue>):<fpage>403</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2005.10.007</pub-id><pub-id pub-id-type="pmid">16890894</pub-id></citation></ref>
<ref id="B42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>S</given-names></name><name><surname>Cariappa</surname><given-names>A</given-names></name></person-group>. <article-title>The follicular versus marginal zone B lymphocyte cell fate decision</article-title>. <source>Nat Rev Immunol</source>. (<year>2009</year>) <volume>9</volume>(<issue>11</issue>):<fpage>767</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/nri2656</pub-id><pub-id pub-id-type="pmid">19855403</pub-id></citation></ref>
<ref id="B43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>JR</given-names></name><name><surname>Sanchez-Diaz</surname><given-names>R</given-names></name><name><surname>Bovolenta</surname><given-names>ER</given-names></name><name><surname>Barreiro</surname><given-names>O</given-names></name><name><surname>Lasarte</surname><given-names>S</given-names></name><name><surname>Matesanz-Marin</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Maintenance of immune tolerance by Foxp3&#x002B; regulatory T cells requires Cd69 expression</article-title>. <source>J Autoimmun</source>. (<year>2014</year>) <volume>55</volume>:<fpage>51</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2014.05.007</pub-id><pub-id pub-id-type="pmid">24934597</pub-id></citation></ref>
<ref id="B44"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schenkel</surname><given-names>JM</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name></person-group>. <article-title>Tissue-resident memory T cells</article-title>. <source>Immunity</source>. (<year>2014</year>) <volume>41</volume>(<issue>6</issue>):<fpage>886</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2014.12.007</pub-id><pub-id pub-id-type="pmid">25526304</pub-id></citation></ref>
<ref id="B45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bagavant</surname><given-names>H</given-names></name><name><surname>Durslewicz</surname><given-names>J</given-names></name><name><surname>Pyclik</surname><given-names>M</given-names></name><name><surname>Makuch</surname><given-names>M</given-names></name><name><surname>Papinska</surname><given-names>JA</given-names></name><name><surname>Deshmukh</surname><given-names>US</given-names></name></person-group>. <article-title>Age-associated B cell infiltration in salivary glands represents a hallmark of Sjogren&#x2019;s-like disease in aging mice</article-title>. <source>Geroscience</source>. (<year>2024</year>) <volume>46</volume>(<issue>6</issue>):<fpage>6085</fpage>&#x2013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-024-01159-3</pub-id><pub-id pub-id-type="pmid">38656650</pub-id></citation></ref>
<ref id="B46"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alimzhanov</surname><given-names>MB</given-names></name><name><surname>Kuprash</surname><given-names>DV</given-names></name><name><surname>Kosco-Vilbois</surname><given-names>MH</given-names></name><name><surname>Luz</surname><given-names>A</given-names></name><name><surname>Turetskaya</surname><given-names>RL</given-names></name><name><surname>Tarakhovsky</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Abnormal development of secondary lymphoid tissues in lymphotoxin Beta-deficient mice</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>1997</year>) <volume>94</volume>(<issue>17</issue>):<fpage>9302</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.94.17.9302</pub-id><pub-id pub-id-type="pmid">9256477</pub-id></citation></ref>
<ref id="B47"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Takematsu</surname><given-names>H</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Miyake</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Fujinawa</surname><given-names>R</given-names></name><etal/></person-group> <article-title>Germinal center marker Gl7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid Species involved in the negative modulation of B-cell activation</article-title>. <source>Mol Cell Biol</source>. (<year>2007</year>) <volume>27</volume>(<issue>8</issue>):<fpage>3008</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.02047-06</pub-id><pub-id pub-id-type="pmid">17296732</pub-id></citation></ref>
<ref id="B48"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haberman</surname><given-names>AM</given-names></name><name><surname>Gonzalez</surname><given-names>DG</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>TT</given-names></name><name><surname>Kerfoot</surname><given-names>SM</given-names></name></person-group>. <article-title>Germinal center B cell initiation, gc maturation, and the coevolution of its stromal cell niches</article-title>. <source>Immunol Rev</source>. (<year>2019</year>) <volume>288</volume>(<issue>1</issue>):<fpage>10</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12731</pub-id><pub-id pub-id-type="pmid">30874342</pub-id></citation></ref>
<ref id="B49"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rheinheimer</surname><given-names>BA</given-names></name><name><surname>Pasquale</surname><given-names>MC</given-names></name><name><surname>Genomics</surname><given-names>NN</given-names></name><name><surname>Computational Biology</surname><given-names>C</given-names></name><name><surname>Limesand</surname><given-names>KH</given-names></name><name><surname>Hoffman</surname><given-names>MP</given-names></name><etal/></person-group> <article-title>Evaluating the transcriptional landscape and cell-cell communication networks in chronically irradiated parotid glands</article-title>. <source>iScience</source>. (<year>2023</year>) <volume>26</volume>(<issue>5</issue>):<fpage>106660</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2023.106660</pub-id><pub-id pub-id-type="pmid">37168562</pub-id></citation></ref>
<ref id="B50"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmberg</surname><given-names>KV</given-names></name><name><surname>Hoffman</surname><given-names>MP</given-names></name></person-group>. <article-title>Anatomy, biogenesis and regeneration of salivary glands</article-title>. <source>Monogr Oral Sci</source>. (<year>2014</year>) <volume>24</volume>:<fpage>1</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1159/000358776</pub-id><pub-id pub-id-type="pmid">24862590</pub-id></citation></ref>
<ref id="B51"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>FAR</given-names></name><name><surname>Pascoal</surname><given-names>LB</given-names></name><name><surname>Dotti</surname><given-names>I</given-names></name><name><surname>Setsuko Ayrizono</surname><given-names>ML</given-names></name><name><surname>Aguilar</surname><given-names>D</given-names></name><name><surname>Rodrigues</surname><given-names>BL</given-names></name><etal/></person-group> <article-title>Whole transcriptional analysis identifies markers of B, T and plasma cell signaling pathways in the mesenteric adipose tissue associated with Crohn&#x2019;s disease</article-title>. <source>J Transl Med</source>. (<year>2020</year>) <volume>18</volume>(<issue>1</issue>):<fpage>44</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-020-02220-3</pub-id><pub-id pub-id-type="pmid">32000799</pub-id></citation></ref>
<ref id="B52"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flach</surname><given-names>H</given-names></name><name><surname>Rosenbaum</surname><given-names>M</given-names></name><name><surname>Duchniewicz</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>SL</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name><etal/></person-group> <article-title>Mzb1 protein regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells</article-title>. <source>Immunity</source>. (<year>2010</year>) <volume>33</volume>(<issue>5</issue>):<fpage>723</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2010.11.013</pub-id><pub-id pub-id-type="pmid">21093319</pub-id></citation></ref>
<ref id="B53"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>B</given-names></name><name><surname>Kasinath</surname><given-names>V</given-names></name><name><surname>Ashton-Rickardt</surname><given-names>GP</given-names></name><name><surname>Clancy</surname><given-names>T</given-names></name><name><surname>Uchimura</surname><given-names>K</given-names></name><name><surname>Tsokos</surname><given-names>G</given-names></name><etal/></person-group> <article-title>High endothelial venules as potential gateways for therapeutics</article-title>. <source>Trends Immunol</source>. (<year>2022</year>) <volume>43</volume>(<issue>9</issue>):<fpage>728</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2022.07.002</pub-id><pub-id pub-id-type="pmid">35931612</pub-id></citation></ref>
<ref id="B54"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veerman</surname><given-names>K</given-names></name><name><surname>Tardiveau</surname><given-names>C</given-names></name><name><surname>Martins</surname><given-names>F</given-names></name><name><surname>Coudert</surname><given-names>J</given-names></name><name><surname>Girard</surname><given-names>JP</given-names></name></person-group>. <article-title>Single-cell analysis reveals heterogeneity of high endothelial venules and different regulation of genes controlling lymphocyte entry to lymph nodes</article-title>. <source>Cell Rep</source>. (<year>2019</year>) <volume>26</volume>(<issue>11</issue>):<fpage>3116</fpage>&#x2013;<lpage>31.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2019.02.042</pub-id><pub-id pub-id-type="pmid">30865898</pub-id></citation></ref>
<ref id="B55"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>S</given-names></name><name><surname>Nagashima</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>VB</given-names></name><name><surname>Peck</surname><given-names>AB</given-names></name><name><surname>Humphreys-Beher</surname><given-names>MG</given-names></name></person-group>. <article-title>Two nod idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren&#x2019;s syndrome) on a healthy murine background</article-title>. <source>Arthritis Rheum</source>. (<year>2002</year>) <volume>46</volume>(<issue>5</issue>):<fpage>1390</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/art.10258</pub-id><pub-id pub-id-type="pmid">12115247</pub-id></citation></ref>
<ref id="B56"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>CQ</given-names></name><name><surname>Gao</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Saban</surname><given-names>DR</given-names></name><name><surname>Cornelius</surname><given-names>JG</given-names></name><name><surname>Peck</surname><given-names>AB</given-names></name></person-group>. <article-title>Il-4-Stat6 signal transduction-dependent induction of the clinical phase of Sjogren&#x2019;s syndrome-like disease of the nonobese diabetic mouse</article-title>. <source>J Immunol</source>. (<year>2007</year>) <volume>179</volume>(<issue>1</issue>):<fpage>382</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.179.1.382</pub-id><pub-id pub-id-type="pmid">17579059</pub-id></citation></ref>
<ref id="B57"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>CA</given-names></name><name><surname>Sutherland</surname><given-names>AP</given-names></name><name><surname>Groom</surname><given-names>JR</given-names></name><name><surname>Batten</surname><given-names>ML</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Gommerman</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Development of nephritis but not sialadenitis in autoimmune-prone baff transgenic mice lacking marginal zone B cells</article-title>. <source>Eur J Immunol</source>. (<year>2006</year>) <volume>36</volume>(<issue>9</issue>):<fpage>2504</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200636270</pub-id><pub-id pub-id-type="pmid">16906535</pub-id></citation></ref>
<ref id="B58"><label>58.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Suresh</surname><given-names>L</given-names></name><name><surname>Xian</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>N</given-names></name><name><surname>Chaves</surname><given-names>LD</given-names></name><etal/></person-group> <article-title>Central role for marginal zone B cells in an animal model of Sjogren&#x2019;s syndrome</article-title>. <source>Clin Immunol</source>. (<year>2016</year>) <volume>168</volume>:<fpage>30</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2016.04.008</pub-id><pub-id pub-id-type="pmid">27140729</pub-id></citation></ref>
<ref id="B59"><label>59.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nocturne</surname><given-names>G</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name></person-group>. <article-title>B cells in the pathogenesis of primary sjogren syndrome</article-title>. <source>Nat Rev Rheumatol</source>. (<year>2018</year>) <volume>14</volume>(<issue>3</issue>):<fpage>133</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2018.1</pub-id><pub-id pub-id-type="pmid">29416129</pub-id></citation></ref>
<ref id="B60"><label>60.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baumgarth</surname><given-names>N</given-names></name></person-group>. <article-title>The double life of a B-1 cell: self-reactivity selects for protective effector functions</article-title>. <source>Nat Rev Immunol</source>. (<year>2011</year>) <volume>11</volume>(<issue>1</issue>):<fpage>34</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1038/nri2901</pub-id><pub-id pub-id-type="pmid">21151033</pub-id></citation></ref>
<ref id="B61"><label>61.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diana</surname><given-names>J</given-names></name><name><surname>Simoni</surname><given-names>Y</given-names></name><name><surname>Furio</surname><given-names>L</given-names></name><name><surname>Beaudoin</surname><given-names>L</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><name><surname>Barrat</surname><given-names>F</given-names></name><etal/></person-group> <article-title>Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes</article-title>. <source>Nat Med</source>. (<year>2013</year>) <volume>19</volume>(<issue>1</issue>):<fpage>65</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3042</pub-id><pub-id pub-id-type="pmid">23242473</pub-id></citation></ref>
<ref id="B62"><label>62.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><etal/></person-group> <article-title>B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via tlr-mediated syk activation</article-title>. <source>Cell Mol Immunol</source>. (<year>2023</year>) <volume>20</volume>(<issue>8</issue>):<fpage>881</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-023-01049-2</pub-id><pub-id pub-id-type="pmid">37291237</pub-id></citation></ref>
<ref id="B63"><label>63.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cerutti</surname><given-names>A</given-names></name><name><surname>Cols</surname><given-names>M</given-names></name><name><surname>Puga</surname><given-names>I</given-names></name></person-group>. <article-title>Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes</article-title>. <source>Nat Rev Immunol</source>. (<year>2013</year>) <volume>13</volume>(<issue>2</issue>):<fpage>118</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/nri3383</pub-id><pub-id pub-id-type="pmid">23348416</pub-id></citation></ref>
<ref id="B64"><label>64.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daridon</surname><given-names>C</given-names></name><name><surname>Pers</surname><given-names>JO</given-names></name><name><surname>Devauchelle</surname><given-names>V</given-names></name><name><surname>Martins-Carvalho</surname><given-names>C</given-names></name><name><surname>Hutin</surname><given-names>P</given-names></name><name><surname>Pennec</surname><given-names>YL</given-names></name><etal/></person-group> <article-title>Identification of transitional type ii B cells in the salivary glands of patients with Sjogren&#x2019;s syndrome</article-title>. <source>Arthritis Rheum</source>. (<year>2006</year>) <volume>54</volume>(<issue>7</issue>):<fpage>2280</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/art.21936</pub-id><pub-id pub-id-type="pmid">16802367</pub-id></citation></ref>
<ref id="B65"><label>65.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyagawa-Hayashino</surname><given-names>A</given-names></name><name><surname>Yoshifuji</surname><given-names>H</given-names></name><name><surname>Kitagori</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Oku</surname><given-names>T</given-names></name><name><surname>Hirayama</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>Increase of Mzb1 in B cells in systemic lupus erythematosus: proteomic analysis of biopsied lymph nodes</article-title>. <source>Arthritis Res Ther</source>. (<year>2018</year>) <volume>20</volume>(<issue>1</issue>):<fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/s13075-018-1511-5</pub-id><pub-id pub-id-type="pmid">29382365</pub-id></citation></ref>
<ref id="B66"><label>66.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogembo</surname><given-names>JG</given-names></name><name><surname>Kannan</surname><given-names>L</given-names></name><name><surname>Ghiran</surname><given-names>I</given-names></name><name><surname>Nicholson-Weller</surname><given-names>A</given-names></name><name><surname>Finberg</surname><given-names>RW</given-names></name><name><surname>Tsokos</surname><given-names>GC</given-names></name><etal/></person-group> <article-title>Human complement receptor type 1/Cd35 is an Epstein&#x2013;Barr virus receptor</article-title>. <source>Cell Rep</source>. (<year>2013</year>) <volume>3</volume>(<issue>2</issue>):<fpage>371</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2013.01.023</pub-id><pub-id pub-id-type="pmid">23416052</pub-id></citation></ref>
<ref id="B67"><label>67.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nocturne</surname><given-names>G</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name></person-group>. <article-title>Sjogren syndrome-associated lymphomas: an update on pathogenesis and management</article-title>. <source>Br J Haematol</source>. (<year>2015</year>) <volume>168</volume>(<issue>3</issue>):<fpage>317</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1111/bjh.13192</pub-id><pub-id pub-id-type="pmid">25316606</pub-id></citation></ref>
<ref id="B68"><label>68.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Royer</surname><given-names>B</given-names></name><name><surname>Cazals-Hatem</surname><given-names>D</given-names></name><name><surname>Sibilia</surname><given-names>J</given-names></name><name><surname>Agbalika</surname><given-names>F</given-names></name><name><surname>Cayuela</surname><given-names>JM</given-names></name><name><surname>Soussi</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Lymphomas in patients with Sjogren&#x2019;s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses</article-title>. <source>Blood</source>. (<year>1997</year>) <volume>90</volume>(<issue>2</issue>):<fpage>766</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V90.2.766</pub-id><pub-id pub-id-type="pmid">9226177</pub-id></citation></ref>
<ref id="B69"><label>69.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinmetz</surname><given-names>TD</given-names></name><name><surname>Verstappen</surname><given-names>GM</given-names></name><name><surname>Suurmond</surname><given-names>J</given-names></name><name><surname>Kroese</surname><given-names>FGM</given-names></name></person-group>. <article-title>Targeting plasma cells in systemic autoimmune rheumatic diseases - promises and pitfalls</article-title>. <source>Immunol Lett</source>. (<year>2023</year>) <volume>260</volume>:<fpage>44</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2023.06.005</pub-id><pub-id pub-id-type="pmid">37315847</pub-id></citation></ref>
<ref id="B70"><label>70.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Domeier</surname><given-names>PP</given-names></name><name><surname>Schell</surname><given-names>SL</given-names></name><name><surname>Rahman</surname><given-names>ZS</given-names></name></person-group>. <article-title>Spontaneous germinal centers and autoimmunity</article-title>. <source>Autoimmunity</source>. (<year>2017</year>) <volume>50</volume>(<issue>1</issue>):<fpage>4</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1080/08916934.2017.1280671</pub-id><pub-id pub-id-type="pmid">28166685</pub-id></citation></ref>
<ref id="B71"><label>71.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theander</surname><given-names>E</given-names></name><name><surname>Vasaitis</surname><given-names>L</given-names></name><name><surname>Baecklund</surname><given-names>E</given-names></name><name><surname>Nordmark</surname><given-names>G</given-names></name><name><surname>Warfvinge</surname><given-names>G</given-names></name><name><surname>Liedholm</surname><given-names>R</given-names></name><etal/></person-group> <article-title>Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren&#x2019;s syndrome</article-title>. <source>Ann Rheum Dis</source>. (<year>2011</year>) <volume>70</volume>(<issue>8</issue>):<fpage>1363</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2010.144782</pub-id><pub-id pub-id-type="pmid">21715359</pub-id></citation></ref>
<ref id="B72"><label>72.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiripolsky</surname><given-names>J</given-names></name><name><surname>McCabe</surname><given-names>LG</given-names></name><name><surname>Kramer</surname><given-names>JM</given-names></name></person-group>. <article-title>Innate immunity in Sjogren&#x2019;s syndrome</article-title>. <source>Clin Immunol</source>. (<year>2017</year>) <volume>182</volume>:<fpage>4</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2017.04.003</pub-id><pub-id pub-id-type="pmid">28396235</pub-id></citation></ref>
<ref id="B73"><label>73.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>JC</given-names></name><name><surname>Baer</surname><given-names>AN</given-names></name><name><surname>Shah</surname><given-names>AA</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><name><surname>Shiboski</surname><given-names>CH</given-names></name><name><surname>Rosen</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Molecular subsetting of interferon pathways in Sjogren&#x2019;s syndrome</article-title>. <source>Arthritis Rheumatol</source>. (<year>2015</year>) <volume>67</volume>(<issue>9</issue>):<fpage>2437</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1002/art.39204</pub-id><pub-id pub-id-type="pmid">25988820</pub-id></citation></ref>
<ref id="B74"><label>74.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trutschel</surname><given-names>D</given-names></name><name><surname>Bost</surname><given-names>P</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name><name><surname>Bondet</surname><given-names>V</given-names></name><name><surname>Llibre</surname><given-names>A</given-names></name><name><surname>Posseme</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Variability of primary Sjogren&#x2019;s syndrome is driven by interferon-alpha and interferon-alpha blood levels are associated with the class ii hla-dq locus</article-title>. <source>Arthritis Rheumatol</source>. (<year>2022</year>) <volume>74</volume>(<issue>12</issue>):<fpage>1991</fpage>&#x2013;<lpage>2002</lpage>. <pub-id pub-id-type="doi">10.1002/art.42265</pub-id><pub-id pub-id-type="pmid">35726083</pub-id></citation></ref>
<ref id="B75"><label>75.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lessard</surname><given-names>CJ</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Adrianto</surname><given-names>I</given-names></name><name><surname>Ice</surname><given-names>JA</given-names></name><name><surname>Rasmussen</surname><given-names>A</given-names></name><name><surname>Grundahl</surname><given-names>KM</given-names></name><etal/></person-group> <article-title>Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren&#x2019;s syndrome</article-title>. <source>Nat Genet</source>. (<year>2013</year>) <volume>45</volume>(<issue>11</issue>):<fpage>1284</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2792</pub-id><pub-id pub-id-type="pmid">24097067</pub-id></citation></ref>
<ref id="B76"><label>76.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>L</given-names></name><name><surname>Girard</surname><given-names>JP</given-names></name></person-group>. <article-title>High endothelial venules (hevs) in immunity, inflammation and cancer</article-title>. <source>Angiogenesis</source>. (<year>2021</year>) <volume>24</volume>(<issue>4</issue>):<fpage>719</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/s10456-021-09792-8</pub-id><pub-id pub-id-type="pmid">33956259</pub-id></citation></ref>
<ref id="B77"><label>77.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>RA</given-names></name><name><surname>Kennedy</surname><given-names>SM</given-names></name><name><surname>Wood</surname><given-names>SG</given-names></name><name><surname>Bolstad</surname><given-names>AI</given-names></name><name><surname>Bienkowska</surname><given-names>J</given-names></name><name><surname>Papandile</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Lymphotoxin-beta receptor blockade reduces Cxcl13 in lacrimal glands and improves corneal integrity in the nod model of Sjogren&#x2019;s syndrome</article-title>. <source>Arthritis Res Ther</source>. (<year>2011</year>) <volume>13</volume>(<issue>6</issue>):<fpage>R182</fpage>. <pub-id pub-id-type="doi">10.1186/ar3507</pub-id><pub-id pub-id-type="pmid">22044682</pub-id></citation></ref>
<ref id="B78"><label>78.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Into</surname><given-names>T</given-names></name><name><surname>Niida</surname><given-names>S</given-names></name><name><surname>Shibata</surname><given-names>KI</given-names></name></person-group>. <article-title>Myd88 signaling causes autoimmune sialadenitis through formation of high endothelial venules and upregulation of ltbeta receptor-mediated signaling</article-title>. <source>Sci Rep</source>. (<year>2018</year>) <volume>8</volume>(<issue>1</issue>):<fpage>14272</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-32690-x</pub-id><pub-id pub-id-type="pmid">30250175</pub-id></citation></ref>
<ref id="B79"><label>79.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trockenbacher</surname><given-names>A</given-names></name><name><surname>Suckow</surname><given-names>V</given-names></name><name><surname>Foerster</surname><given-names>J</given-names></name><name><surname>Winter</surname><given-names>J</given-names></name><name><surname>Krauss</surname><given-names>S</given-names></name><name><surname>Ropers</surname><given-names>HH</given-names></name><etal/></person-group> <article-title>Mid1, mutated in opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2a for degradation</article-title>. <source>Nat Genet</source>. (<year>2001</year>) <volume>29</volume>(<issue>3</issue>):<fpage>287</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1038/ng762</pub-id><pub-id pub-id-type="pmid">11685209</pub-id></citation></ref>
<ref id="B80"><label>80.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zaghlula</surname><given-names>M</given-names></name><name><surname>Walters</surname><given-names>E</given-names></name><name><surname>Cox</surname><given-names>TC</given-names></name><name><surname>Massiah</surname><given-names>MA</given-names></name></person-group>. <article-title>The Mid1 E3 ligase catalyzes the polyubiquitination of Alpha4 (Alpha4), a regulatory subunit of protein phosphatase 2a (Pp2a): novel insights into Mid1-mediated regulation of Pp2a</article-title>. <source>J Biol Chem</source>. (<year>2013</year>) <volume>288</volume>(<issue>29</issue>):<fpage>21341</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.481093</pub-id><pub-id pub-id-type="pmid">23740247</pub-id></citation></ref>
<ref id="B81"><label>81.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inui</surname><given-names>S</given-names></name><name><surname>Sanjo</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Miyamoto</surname><given-names>E</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name></person-group>. <article-title>Ig receptor binding protein 1 (Alpha4) is associated with a rapamycin-sensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein phosphatase 2a</article-title>. <source>Blood</source>. (<year>1998</year>) <volume>92</volume>(<issue>2</issue>):<fpage>539</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V92.2.539</pub-id><pub-id pub-id-type="pmid">9657754</pub-id></citation></ref>
<ref id="B82"><label>82.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>M</given-names></name><name><surname>Edman</surname><given-names>MC</given-names></name><name><surname>Reddy Janga</surname><given-names>S</given-names></name><name><surname>Yarber</surname><given-names>F</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Klinngam</surname><given-names>W</given-names></name><etal/></person-group> <article-title>Rapamycin eye drops suppress lacrimal gland inflammation in a murine model of Sjogren&#x2019;s syndrome</article-title>. <source>Invest Ophthalmol Vis Sci</source>. (<year>2017</year>) <volume>58</volume>(<issue>1</issue>):<fpage>372</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.16-19159</pub-id><pub-id pub-id-type="pmid">28122086</pub-id></citation></ref>
<ref id="B83"><label>83.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>KA</given-names></name><etal/></person-group> <article-title>Metformin improves salivary gland inflammation and hypofunction in murine Sjogren&#x2019;s syndrome</article-title>. <source>Arthritis Res Ther</source>. (<year>2019</year>) <volume>21</volume>(<issue>1</issue>):<fpage>136</fpage>. <pub-id pub-id-type="doi">10.1186/s13075-019-1904-0</pub-id><pub-id pub-id-type="pmid">31164166</pub-id></citation></ref>
<ref id="B84"><label>84.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Knutzen</surname><given-names>CA</given-names></name><name><surname>Krauss</surname><given-names>S</given-names></name><name><surname>Schweiger</surname><given-names>S</given-names></name><name><surname>Chiang</surname><given-names>GG</given-names></name></person-group>. <article-title>Control of Mtorc1 signaling by the opitz syndrome protein Mid1</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2011</year>) <volume>108</volume>(<issue>21</issue>):<fpage>8680</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1100131108</pub-id><pub-id pub-id-type="pmid">21555591</pub-id></citation></ref>
<ref id="B85"><label>85.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabapathy</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Kallunki</surname><given-names>T</given-names></name><name><surname>Schreiber</surname><given-names>M</given-names></name><name><surname>David</surname><given-names>JP</given-names></name><name><surname>Jochum</surname><given-names>W</given-names></name><etal/></person-group> <article-title>Jnk2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development</article-title>. <source>Curr Biol</source>. (<year>1999</year>) <volume>9</volume>(<issue>3</issue>):<fpage>116</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/s0960-9822(99)80065-7</pub-id><pub-id pub-id-type="pmid">10021384</pub-id></citation></ref>
<ref id="B86"><label>86.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaeschke</surname><given-names>A</given-names></name><name><surname>Karasarides</surname><given-names>M</given-names></name><name><surname>Ventura</surname><given-names>JJ</given-names></name><name><surname>Ehrhardt</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><etal/></person-group> <article-title>Jnk2 is a positive regulator of the cjun transcription factor</article-title>. <source>Mol Cell</source>. (<year>2006</year>) <volume>23</volume>(<issue>6</issue>):<fpage>899</fpage>&#x2013;<lpage>911</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2006.07.028</pub-id><pub-id pub-id-type="pmid">16973441</pub-id></citation></ref>
<ref id="B87"><label>87.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zoukhri</surname><given-names>D</given-names></name><name><surname>Macari</surname><given-names>E</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Kublin</surname><given-names>CL</given-names></name></person-group>. <article-title>C-Jun Nh2-terminal kinase mediates interleukin-1beta-induced inhibition of lacrimal gland secretion</article-title>. <source>J Neurochem</source>. (<year>2006</year>) <volume>96</volume>(<issue>1</issue>):<fpage>126</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03529.x</pub-id><pub-id pub-id-type="pmid">16300639</pub-id></citation></ref>
<ref id="B88"><label>88.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaeschke</surname><given-names>A</given-names></name><name><surname>Rincon</surname><given-names>M</given-names></name><name><surname>Doran</surname><given-names>B</given-names></name><name><surname>Reilly</surname><given-names>J</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Greiner</surname><given-names>DL</given-names></name><etal/></person-group> <article-title>Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2005</year>) <volume>102</volume>(<issue>19</issue>):<fpage>6931</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0502143102</pub-id><pub-id pub-id-type="pmid">15867147</pub-id></citation></ref>
<ref id="B89"><label>89.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harterink</surname><given-names>M</given-names></name><name><surname>Vocking</surname><given-names>K</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Soriano Jerez</surname><given-names>EM</given-names></name><name><surname>Slenders</surname><given-names>L</given-names></name><name><surname>Freal</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Trim46 organizes microtubule fasciculation in the axon initial segment</article-title>. <source>J Neurosci</source>. (<year>2019</year>) <volume>39</volume>(<issue>25</issue>):<fpage>4864</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3105-18.2019</pub-id><pub-id pub-id-type="pmid">30967428</pub-id></citation></ref>
<ref id="B90"><label>90.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pramanik</surname><given-names>R</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Borowicz</surname><given-names>S</given-names></name><name><surname>Choubey</surname><given-names>D</given-names></name><name><surname>Schultz</surname><given-names>RM</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><etal/></person-group> <article-title>P38 isoforms have opposite effects on ap-1-dependent transcription through regulation of C-jun. The determinant roles of the isoforms in the P38 mapk signal specificity</article-title>. <source>J Biol Chem</source>. (<year>2003</year>) <volume>278</volume>(<issue>7</issue>):<fpage>4831</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M207732200</pub-id><pub-id pub-id-type="pmid">12475989</pub-id></citation></ref></ref-list>
</back>
</article>